var title_f26_29_27088="Thyroid hormone synthesis";
var content_f26_29_27088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Thyroid hormone biosynthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thyroid hormone synthesis includes the following steps: (1) iodide (I",
"    <sup>",
"     -",
"    </sup>",
"    ) trapping by the thyroid follicular cells; (2) diffusion of iodide to the apex of the cells; (3) transport of iodide into the colloid; (4) oxidation of inorganic iodide to iodine and incorporation of iodine into tyrosine residues within thyroglobulin molecules in the colloid; (5) combination of two diiodotyrosine (DIT) molecules to form tetraiodothyronine (thyroxine, T4) or of monoiodotyrosine (MIT) with DIT to form triiodothyronine (T3); (6) uptake of thyroglobulin from the colloid into the follicular cell by endocytosis, fusion of the thyroglobulin with a lysosome, and proteolysis and release of T4, T3, DIT, and MIT; (7) release of T4 and T3 into the circulation; and (8) deiodination of DIT and MIT to yield tyrosine. T3 is also formed from monodeiodination of T4 in the thyroid and in peripheral tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Scientific American Medicine, Scientific American, New York, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27088=[""].join("\n");
var outline_f26_29_27088=null;
var title_f26_29_27089="Beta thalassemia intermedia";
var content_f26_29_27089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear in beta thalassemia intermedia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear from a patient with beta thalassemia intermedia post-splenectomy. This field shows target cells, hypochromic cells, microcytic cells, red cell fragments, red cells with bizarre shapes, and a single nucleated red cell (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27089=[""].join("\n");
var outline_f26_29_27089=null;
var title_f26_29_27090="Patient information: Headaches in children (The Basics)";
var content_f26_29_27090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/45/40658\">",
"         Patient information: Head injury in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/51/16179\">",
"         Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/15/36086\">",
"         Patient information: Headache in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/59/42931\">",
"         Patient information: Headache treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/57/35731\">",
"         Patient information: Migraine headaches in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Headaches in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/headaches-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15868628\">",
"      <span class=\"h1\">",
"       What types of headaches do children get?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Headaches are common in children. Two of the most common types of headaches in children are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Tension-type headaches",
"        </strong>",
"        &ndash; Tension-type headaches cause pressure or tightness on both the left and right sides of the head. Tension headaches are usually not severe enough to keep children from doing their daily activities, such as going to school.",
"       </li>",
"       <li>",
"        <strong>",
"         Migraine headaches",
"        </strong>",
"        &ndash; Migraine headaches often start off mild and then get worse. They might affect just one side of the head or both. They can cause your child to feel sick or vomit or make your child sensitive to light and sound. They can also cause temporary problems with vision. For example, before getting a migraine, some children see spots or colored lights. When they have a migraine, children are often not able to do their normal daily activities, such as go to school.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children also tend to get headaches that go along with a cold, the flu, a sore throat, or a sinus infection",
"     </p>",
"     <p>",
"      In rare cases headaches in children are caused by a serious infection (such as meningitis), severe high blood pressure, or brain tumors.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868644\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or a nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should take your child to the doctor right away (without giving any medicine) if he or she has a headache that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts after a head injury",
"       </li>",
"       <li>",
"        Wakes him or her up",
"       </li>",
"       <li>",
"        Is sudden and severe and happens with other symptoms, such as:",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Neck pain or stiffness",
"       </li>",
"       <li>",
"        Double vision or changes in vision",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Loss of balance",
"       </li>",
"       <li>",
"        Fever of 100.4&deg;F (38&deg;C) or higher",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also take your child to see a doctor or nurse if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Gets headaches more than once a month",
"       </li>",
"       <li>",
"        Has a headache and is younger than 3 years old",
"       </li>",
"       <li>",
"        Has a headache and has certain medical conditions, such as sickle cell disease, bleeding problems, immune system problems, genetic problems, heart problems, or cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868661\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child&rsquo;s headache does not fit the descriptions above, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have your child rest in a quiet dark room with a cool cloth on his or her forehead.",
"       </li>",
"       <li>",
"        Encourage your child to sleep, if he or she wants to. Sleep can help, especially with migraine headaches.",
"       </li>",
"       <li>",
"        Give your child pain medicine, such as children&rsquo;s",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or children&rsquo;s",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;). Never give your child",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        . In children, aspirin can cause a life-threatening condition called Reye syndrome.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868678\">",
"      <span class=\"h1\">",
"       Are there tests my child should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Most headaches in children are not caused by a serious problem.",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor or nurse will probably be able to tell what is wrong with your child by doing an exam and by learning about his or her symptoms. But if your child&rsquo;s doctor or nurse suspects a serious infection or problem, he or she might order an imaging test such as an MRI or a CT scan. Imaging tests create images of the inside of the body. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868693\">",
"      <span class=\"h1\">",
"       How are headaches in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many types of medicines used to treat and to prevent headaches. Your child&rsquo;s doctor or nurse will decide which medicine, if any, would work best for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868710\">",
"      <span class=\"h1\">",
"       Is there anything I can do to keep my child from getting headaches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some headaches can be triggered by certain foods or things that children do. Keep a &ldquo;headache diary&rdquo; for your child. In the diary, write down every time your child has a headache and what he or she ate and did before it started. That way, you can find out if there is anything he or she should avoid.",
"     </p>",
"     <p>",
"      Some common headache triggers are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skipping meals",
"       </li>",
"       <li>",
"        Not drinking enough fluids",
"       </li>",
"       <li>",
"        Having too little or too much caffeine",
"       </li>",
"       <li>",
"        Sleeping too much or too little",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"       <li>",
"        Certain foods, such as bologna or hot dogs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868727\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=see_link\">",
"       Patient information: Head injury in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"       Patient information: Headache in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       Patient information: Headache treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"       Patient information: Migraine headaches in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/29/27090?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17166 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27090=[""].join("\n");
var outline_f26_29_27090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868628\">",
"      What types of headaches do children get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868644\">",
"      Should my child see a doctor or a nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868661\">",
"      Is there anything I can do on my own to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868678\">",
"      Are there tests my child should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868693\">",
"      How are headaches in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868710\">",
"      Is there anything I can do to keep my child from getting headaches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868727\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=related_link\">",
"      Patient information: Migraine headaches in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27091="Benzonatate: Patient drug information";
var content_f26_29_27091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzonatate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/1/18451?source=see_link\">",
"     see \"Benzonatate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tessalon&reg;;",
"     </li>",
"     <li>",
"      Zonatuss&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzonatate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3501426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep this drug away from children. There have been overdoses with it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11220 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27091=[""].join("\n");
var outline_f26_29_27091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140009\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014655\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014654\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014659\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014660\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014662\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014657\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014658\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014663\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014664\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/1/18451?source=related_link\">",
"      Benzonatate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27092="Normal trachea CXR";
var content_f26_29_27092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 542px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal chest radiograph demonstrates the entire trachea and the tracheal bifurcation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27092=[""].join("\n");
var outline_f26_29_27092=null;
var title_f26_29_27093="Vorinostat: Drug information";
var content_f26_29_27093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vorinostat: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/8/36997?source=see_link\">",
"    see \"Vorinostat: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3362703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zolinza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zolinza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3362707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Histone Deacetylase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3362740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cutaneous T-cell lymphoma:",
"     </b>",
"     Oral: 400 mg once daily until disease progression or unacceptable toxicity",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3362741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3362742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (not studied); however, based on the minimal renal elimination, adjustment not expected.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3362743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Use with caution in mild-to-moderate impairment (based on hepatic metabolism):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild impairment (total bilirubin &gt;1 to 1.5 times ULN",
"     <b>",
"      or",
"     </b>",
"     total bilirubin &le;ULN and AST &gt;ULN): 300 mg once daily (Ramalingam, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN): 200 mg once daily (Ramalingam, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (total bilirubin &gt;3 times ULN): Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate impairment (total bilirubin 1.5-3 times ULN): Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (total bilirubin &gt;3 times ULN): Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3362744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intolerance: Reduce dose to 300 mg once daily; if needed, may further reduce to 300 mg daily for 5 consecutive days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In clinical trials,",
"     <b>",
"      dose reductions",
"     </b>",
"     were instituted for the following adverse events: Increased serum creatinine, decreased appetite, hypokalemia, leukopenia, nausea, neutropenia, thrombocytopenia, and vomiting. Vorinostat was",
"     <b>",
"      discontinued",
"     </b>",
"     for the following adverse events: Anemia, angioneurotic edema, weakness, chest pain, exfoliative dermatitis, DVT, ischemic stroke, lethargy, pulmonary embolism, and spinal cord injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment was withheld in clinical trials for grade 4 anemia or thrombocytopenia or other grade 3 or 4 drug related toxicity, until resolved to &le;grade 1. Therapy was reinitiated with dose modification (Olsen, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3362752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zolinza&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3362705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3362746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food. Do not open, crush, or chew capsules. Maintain adequate hydration (&ge;2 L/day fluids) during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3362709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous manifestations of progressive, persistent, or recurrent cutaneous T-cell lymphoma (CTCL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vorinostat may be confused with Votrient&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3362720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (52%), chills (16%), dizziness (15%), headache (12%), fever (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (19%), pruritus (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (8% to 69%; grade 3: 5%), dehydration (1% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (52%), nausea (41%), taste alteration (28%), anorexia (24%), weight loss (21%), xerostomia (16%), constipation (15%), vomiting (15%), appetite decreased (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (26%; grades 3/4: 6%), anemia (14%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (51%), creatinine increased (16% to 47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (11%), upper respiratory infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Squamous cell carcinoma (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary embolism (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, angioneurotic edema, blurred vision, chest pain, cholecystitis, deafness, diverticulitis, dysphagia, DVT, enterococcal infection, exfoliative dermatitis, gastrointestinal bleeding, gastrointestinal hemorrhage, Guillain-Barr&eacute; syndrome, hemoptysis, hypertension, hypokalemia,  hyponatremia, infection, lethargy, leukopenia, MI, neutropenia, pneumonia,  renal failure, sepsis, spinal cord injury, streptococcal bacteremia, stroke (ischemic), syncope, T-cell lymphoma, tumor hemorrhage, ureteric obstruction, ureteropelvic junction obstruction, urinary retention, vasculitis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3362715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to vorinostat or any component of the formulation; severe hepatic impairment (total bilirubin &ge;3 times ULN)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3362716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-related anemia and thrombocytopenia may occur; may require dosage reduction or discontinuation. Monitor blood counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause dizziness or fatigue; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicities: Nausea, vomiting, and diarrhea may occur; antiemetics and antidiarrheals may be required. Replace fluids and electrolytes to avoid dehydration. Control pre-existing nausea and vomiting prior to treatment initiation. Adverse anastomotic healing events have occurred in patients recovering from bowel surgery; use with caution in the perioperative period in patients requiring bowel surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: May cause hyperglycemia. Use with caution in patients with diabetes mellitus; monitor; may require diet and/or therapy modifications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation has been observed with use. Correct electrolyte abnormalities prior to treatment and monitor and correct potassium, calcium, and magnesium levels during therapy. Use caution in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation or with medications known to prolong the QT interval. Baseline and periodic ECGs were done in clinical trials (Duvic, 2007; Olsen, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Pulmonary embolism and deep vein thrombosis (DVT) have been reported; monitor. Use with caution in patients with a history of thrombotic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; dose reductions are recommended  (elimination is predominantly hepatic). Use is contraindicated in severe hepatic impairment. In the Canadian labeling, use is also not recommended in patients with moderate hepatic impairment (total bilirubin 1.5-3 times ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Prolongation of the prothrombin time and INR were observed in patients receiving vorinostat and warfarin; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3362726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Vorinostat may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3362710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3362711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated adverse fetal effects, including fetal loss, decreased fetal weight, and skeletal malformation. Inform patient of potential hazard if used during pregnancy or if pregnancy occurs during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3362713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3362714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to discontinue vorinostat or to discontinue breast-feeding should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3362745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zolinza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $12543.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3362748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential  and serum chemistries, including calcium, magnesium, potassium, glucose and creatinine (baseline, then every 2 weeks for 2 months, then monthly), hepatic function, INR (if on concomitant warfarin therapy), fluid status. Baseline and periodic ECGs were done in clinical trials.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zolinza (AR, AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3362730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of histone deacetylase enzymes, HDAC1, HDAC2, HDAC3, and HDAC6, which catalyze acetyl group removal from protein lysine residues (including histones and transcription factors). Inhibition of histone deacetylase results in accumulation of acetyl groups, which alters chromatin structure and transcription factor activation; cell growth is terminated and apoptosis occurs.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3362732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~71%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Glucuronidated and hydrolyzed (followed by beta-oxidation) to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Fasting:  ~43%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:  ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: With high-fat meal:  ~4 hours (range: 2-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine: 52% (&lt;1% as unchanged drug,  ~52% as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Duvic M, Talpur R, Ni X, et al, &ldquo;Phase II Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-Cell Lymphoma (CTCL),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(1):31-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/16960145/pubmed\" id=\"16960145\" target=\"_blank\">",
"        16960145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly WK, O'Connor OA, Krug LM, et al, &ldquo;Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(17):3923-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/15897550/pubmed\" id=\"15897550\" target=\"_blank\">",
"        15897550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane AA and Chabner BA, &ldquo;Histone Deacetylase Inhibitors in Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5459-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/19826124/pubmed\" id=\"19826124\" target=\"_blank\">",
"        19826124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor OA, Heaney ML, Schwartz L, et al, &ldquo;Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(1):166-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/16330674/pubmed\" id=\"16330674\" target=\"_blank\">",
"        16330674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen EA, Kim YH, Kuzel TM, et al, &ldquo;Phase IIb Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(21):3109-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/17577020/pubmed\" id=\"17577020\" target=\"_blank\">",
"        17577020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramalingam SS, Kummar S, Sarantopoulos J, et al, &ldquo;Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(29):4507-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/29/27093/abstract-text/20837947/pubmed\" id=\"20837947\" target=\"_blank\">",
"        20837947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9491 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27093=[""].join("\n");
var outline_f26_29_27093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362703\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097314\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362707\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362740\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362741\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362742\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362743\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362744\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362752\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362705\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362746\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362709\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402986\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362720\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362715\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362716\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300225\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362726\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362711\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362713\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362714\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362745\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322954\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362748\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190111\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362730\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362732\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/8/36997?source=related_link\">",
"      Vorinostat: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27094="The milk-alkali syndrome";
var content_f26_29_27094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The milk-alkali syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27094/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27094/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27094/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27094/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27094/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/29/27094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The milk-alkali syndrome consists of the triad of hypercalcemia, metabolic alkalosis, and renal insufficiency associated with the ingestion of large amounts of calcium and absorbable alkali. The syndrome was originally described in association with the use of milk and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    for the treatment of peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/1\">",
"     1",
"    </a>",
"    ]. Once a classic cause of hypercalcemia, the milk-alkali syndrome virtually disappeared with the advent of new therapies of peptic ulcer disease, and by 1985 was considered the cause of less than one percent of cases of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there has been a resurgence of this disorder, as it now accounts for up to 12 percent of cases, making it the third leading cause of hypercalcemia behind primary hyperparathyroidism and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) Three factors are responsible for this increase in incidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The emphasis on calcium therapy for the prevention and treatment of osteoporosis",
"     </li>",
"     <li>",
"      Readily available over the counter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      preparations",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      to minimize secondary hyperparathyroidism in patients with chronic renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"       \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic reviews the presentation, pathogenesis and treatment of the milk-alkali syndrome. Other causes of hypercalcemia and alkalosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    .) The treatment of hypercalcemia and alkalosis are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1915, Sippy reported an antacid regimen designed to neutralize gastric acidity and promote the healing of peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/5\">",
"     5",
"    </a>",
"    ]. The regimen included the hourly administration of milk or cream with Sippy powders (a powder containing 600 mg of magnesium carbonate and 600 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    alternating with a powder containing 600 mg of bismuth subcarbonate and 1200 to 1800 mg of sodium bicarbonate). Toxic reactions associated with alkalosis and renal insufficiency were noted shortly thereafter, but the plasma calcium concentration was not measured [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/6\">",
"     6",
"    </a>",
"    ]. In 1936, a report associated hypercalcemia with the alkalosis and renal failure in patients treated with the Sippy regime [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these observations, therapy of peptic ulcer disease continued to include the administration of large doses (20 to 60 gm per day) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    and less acute and more frequent cases were reported. Most cases were middle-aged men, the group with the highest incidence of peptic ulcer disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The milk-alkali syndrome presents a spectrum of disease which is, in part, a function of the amount and duration of the calcium and alkali ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three clinical syndromes were recognized in original descriptions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute &ndash; The acute or toxemic form occurred after approximately one week of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/8\">",
"       8",
"      </a>",
"      ]. The symptoms were those of acute hypercalcemia, and included nausea, vomiting, weakness, and mental changes with psychosis or depressed sensorium. There was also severe metabolic alkalosis, a normal to elevated plasma phosphate concentration, and acute renal insufficiency. Withdrawal of milk and alkali led to rapid relief of symptoms and the return of normal renal function.",
"     </li>",
"     <li>",
"      Chronic &ndash; In the chronic form (also called Burnett's syndrome), patients presented after a long history of high",
"      <span class=\"nowrap\">",
"       milk/alkali",
"      </span>",
"      intake with symptoms of chronic hypercalcemia, such as polyuria, polydipsia, muscle aches, and pruritus [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. Frequently, there was evidence of metastatic calcifications, including band keratopathy and nephrocalcinosis. Laboratory abnormalities were similar to those in the acute syndrome, but the response to withdrawal of milk and alkali was quite different. The muscle aches and pruritus improved slowly as the plasma calcium concentration slowly normalized. However, there was usually minimal or no improvement in renal function, as many patients continued to have chronic renal failure.",
"     </li>",
"     <li>",
"      Subacute or intermediate &ndash; In the subacute form (also called Cope's syndrome), patients were usually seen during therapy with milk and alkali that had been taken intermittently for years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/12\">",
"       12",
"      </a>",
"      ]. Affected patients had symptoms of both acute and chronic hypercalcemia and responded to medication withdrawal with gradual improvement. Renal function remained mildly impaired in some cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Modern presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The milk-alkali syndrome reemerged in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/3,4,13,14\">",
"     3,4,13,14",
"    </a>",
"    ]. One study found that the milk-alkali syndrome accounted for two percent of hospitalized patients with hypercalcemia between 1985 and 1989, as compared with 12 percent between 1990 and 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/3\">",
"     3",
"    </a>",
"    ]. In another study, milk-alkali syndrome accounted for 8.8 percent of hypercalcemia cases between 1998 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients who now present with milk-alkali syndrome are women, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    is the predominant source of calcium and alkali intake. The modern presentation differs from the classical presentation in the following additional respects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are often asymptomatic and the finding of hypercalcemia and renal failure is an incidental discovery.",
"     </li>",
"     <li>",
"      Hypophosphatemia is common, reflecting both the absence of the phosphate load imposed by the milk drinking in the classic cases and the phosphate binding properties of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Hypocalcemia may develop as a result of therapy, possibly reflecting the combination of PTH suppression and the removal of the source of the increased entry of calcium into the circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Betel nut chewing, which is performed in the Far East, Asia, and the South Pacific, is also reportedly a cause of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Since the nuts are bitter, they are wrapped in a compound with Ca(OH)2, which is eventually converted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The milk-alkali syndrome is caused by the ingestion of large amounts of calcium in conjunction with absorbable alkali. However, the fraction of the population at risk who develop sustained hypercalcemia, metabolic alkalosis, and renal insufficiency is relatively small. In one series of 1350 patients treated with the Sippy regimen, approximately 8 percent were affected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/17\">",
"     17",
"    </a>",
"    ]. In another study, 297 heart and lung transplant recipients were prescribed large doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    as prophylaxis for adverse effects of glucocorticoid immunosuppression. Sixty-five patients developed hypercalcemia; 31 were alkalotic at the time of the hypercalcemia, and 37 had an impairment in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is probable that normal renal function and the suppression of calcitriol production allow maintenance of calcium and acid-base balance in most individuals exposed to large doses of calcium and alkali. Under normal circumstances, the fractional intestinal absorption of filtered calcium declines markedly as calcitriol levels fall, and calcium intakes exceeding 4 grams per day are necessary to achieve normal serum levels in the absence of calcitriol. However, net calcium absorption increases markedly when intake is increased to 10 to 15 grams per day despite suppression of calcitriol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, some individuals may not adequately suppress calcitriol in response to large doses of calcium resulting in hyperabsorption of calcium, resulting in hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Possible role of calcitriol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the mechanisms that initiate hypercalcemia are incompletely understood, clinical studies suggest that hypercalcemia underlies the subsequent metabolic derangements including alkalosis and acute kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercalcemia causes the following effects in the kidney:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasoconstriction which decreases the glomerular filtration rate (GFR).",
"     </li>",
"     <li>",
"      Activation of calcium&ndash;sensing receptor in the medullary thick ascending limb which inhibits the Na-K-2Cl cotransporter causing natriuresis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link&amp;anchor=H5#H5\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Urine calcium excretion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The calcium-induced natriuresis results in volume depletion which stimulates the renal tubular absorption of bicarbonate. The combined effects of increased alkali intake, volume depletion and decreased GFR lead to metabolic alkalosis.",
"   </p>",
"   <p>",
"    Alkalosis may contribute to the maintenance of both volume depletion (by enhancing the activity of the calcium-sensing receptor) and hypercalcemia (by increasing calcium reabsorption in the distal tubule via the pH-sensitive calcium channel, the transient receptor potential vanilloid member 5 [TRPV5]) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Volume contraction due to vomiting or diuretics will also worsen the hypercalcemia and alkalosis. Marked hypercalcemia can lead to the patient presenting with acute toxicity. On the other hand, prolonged or intermittent mild hypercalcemia in conjunction with metabolic alkalosis sets the stage for the development of nephrocalcinosis and chronic renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69903827\">",
"    <span class=\"h2\">",
"     Extrarenal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrarenal factors that may contribute to the initial development of hypercalcemia include decreased bone buffering and decreased suppression of calcitriol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69902863\">",
"    <span class=\"h3\">",
"     Decreased bone buffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone provides the chief reservoir for buffering excess calcium. Older patients have a reduced capacity for bone buffering which may cause them to be at higher risk for hypercalcemia following the ingestion of calcium-containing supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Possible role of calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations indicate that some individuals may not suppress calcitriol levels in response to large doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experimental studies indicate that not all normal individuals fed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      suppress calcitriol levels to the same extent, with metabolite levels remaining well within the normal range in some [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The suppression of calcitriol levels by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      administration in patients with idiopathic hypercalciuria is transient, with the levels returning to the normal range after two weeks of continued ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the hypothesis that lack of suppression of calcitriol is an important determinant of susceptibility to the milk-alkali syndrome has not been directly tested, five measurements of plasma calcitriol levels have been reported in patients with the milk-alkali syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Calcitriol was appropriately suppressed in three patients; however, the other two had values of 29 and 34",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    consistent with inadequate suppression.",
"   </p>",
"   <p>",
"    This issue assumes more importance in light of the current emphasis on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    intake for the treatment and prevention of osteoporosis. While recommended doses are only 1.5 g per day, it is likely that some women, unless otherwise instructed, take higher doses. In the absence of a source of phosphate such as milk, calcium carbonate may produce mild hypophosphatemia, which directly increases the synthesis of calcitriol. Increased intake of calcium and alkali in association with high or even normal levels of calcitriol may predispose certain individuals to mild intermittent hypercalcemia at doses lower than those previously reported. Concurrent therapy with vitamin D, for either osteoporosis or secondary hyperparathyroidism in chronic renal failure, makes the development of hypercalcemia much more likely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .) Individuals with mild renal insufficiency, volume contraction, and those treated with a thiazide diuretic (which directly reduces calcium excretion) are also likely to be at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women may have elevated calcitriol levels and increased calcium absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link&amp;anchor=H5#H5\">",
"     \"Calcium physiology in pregnancy\", section on 'Role of 1,25-dihydroxyvitamin D and PTH'",
"    </a>",
"    .) Several cases of milk-alkali syndrome have been reported in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/14,28\">",
"     14,28",
"    </a>",
"    ], which suggests that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    should be used with caution during pregnancy (eg, for the relief of symptoms of reflux).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69903789\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who appear to be at higher risk for milk-alkali syndrome include older individuals, those susceptible to volume depletion (including patients on thiazide diuretics) and those on medications that reduce the GFR, such as angiotensin converting enzyme (ACE) inhibitors; angiotensin receptor blockers (ARBs); or non-steroidal antiinflammatory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27094/abstract/23\">",
"     23",
"    </a>",
"    ]. As described above, pregnant women may also be at increased risk, due to increased calcitriol levels . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link&amp;anchor=H5#H5\">",
"     \"Calcium physiology in pregnancy\", section on 'Role of 1,25-dihydroxyvitamin D and PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69902931\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of milk-alkali syndrome is based upon the history of ingestion of calcium rich medications and the exclusion of other causes of hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69903554\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal of the offending agent, and treatment with isotonic saline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    usually leads to clinical improvement and rapid resolution of the hypercalcemia and metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69903561\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The milk-alkali syndrome consists of the triad of hypercalcemia, metabolic alkalosis, and renal insufficiency associated with the ingestion of calcium and absorbable alkali. Although the syndrome disappeared with new therapies of peptic ulcer disease, there has been a resurgence due to the emphasis on calcium therapy for the prevention and treatment of osteoporosis; readily available over the counter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      preparations; and the use of calcium carbonate to minimize secondary hyperparathyroidism in patients with chronic renal failure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three clinical syndromes have been recognized, including acute, chronic and subacute or intermediate forms, depending on chronicity of symptoms. Compared to the original description, distinguishing features of the modern day presentation include female predominance, incidental discovery and lack of symptoms, over the counter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      as the predominant source of calcium and alkali, and hypophosphatemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) The milk-alkali syndrome starts with the development of hypercalcemia. Hypercalcemia causes a vasoconstriction-induced decline in glomerular filtration rate (GFR), and activation of the calcium&ndash;sensing receptor in the medullary thick ascending limb resulting in natriuresis and volume depletion. The combined effects of increased alkali intake, decreased GFR and volume depletion lead to metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extrarenal mechanisms that may contribute to hypercalcemia in susceptible individuals include decreased bone buffering capacity and insufficient suppression of calcitriol. (See",
"      <a class=\"local\" href=\"#H69902863\">",
"       'Decreased bone buffering'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible role of calcitriol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at higher risk for the development of milk-alkali syndrome include older individuals, those at risk for volume depletion (including patients on thiazide diuretics) and those on medications that reduce the GFR, such as angiotensin converting enzyme (ACE) inhibitors; angiotensin receptor blockers (ARBs); or non-steroidal antiinflammatory agents. Pregnant women may also be at higher risk. (See",
"      <a class=\"local\" href=\"#H69903789\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of milk-alkali syndrome is based upon the history of ingestion of calcium rich medications and the exclusion of other causes of hypercalcemia. (See",
"      <a class=\"local\" href=\"#H69902931\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"       \"Diagnostic approach to hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Withdrawal of the offending agent, and treatment with isotonic saline and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      usually leads to clinical improvement and rapid resolution of the hypercalcemia and metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H69903554\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"       \"Treatment of hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"       \"Treatment of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/1\">",
"      Cope, CL. Base changes in the alkalosis produced by the treatment of gastric ulcer with alkalies. Clin Sci 1936; 2:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/2\">",
"      Jamieson MJ. Hypercalcaemia. Br Med J (Clin Res Ed) 1985; 290:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/3\">",
"      Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995; 74:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/4\">",
"      Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005; 63:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/5\">",
"      Sippy, BW. Gastric and duodenal ulcer: Medical cure by an efficient removal of gastric juice corrosion. JAMA 1915; 64:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/6\">",
"      Hardt, LL, Rivers, AB. Toxic manifestations following the alkaline treatment of peptic ulcer. Arch Intern Med 1923; 31:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/7\">",
"      Orwoll ES. The milk-alkali syndrome: current concepts. Ann Intern Med 1982; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/8\">",
"      Cooke, AM. Alkalosis occurring in the alkaline treatment of peptic ulcers. Quart J Med 1932; 25:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/9\">",
"      BURNETT CH, COMMONS RR. Hypercalcemia without hypercalcuria or hypophosphatemia, calcinosis and renal insufficiency; a syndrome following prolonged intake of milk and alkali. N Engl J Med 1949; 240:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/10\">",
"      Junor BJ, Catto GR. Renal biopsy in the milk-alkali syndrome. J Clin Pathol 1976; 29:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/11\">",
"      Kallmeyer JC, Funston MR. The milk-alkali syndrome. A case report. S Afr Med J 1983; 64:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/12\">",
"      PUNSAR S, SOMER T. The milk-alkali syndrome. A report of three illustrative cases and a review of the literature. Acta Med Scand 1963; 173:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/13\">",
"      McGuinness B, Logan JI. Milk alkali syndrome. Ulster Med J 2002; 71:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/14\">",
"      Picolos MK, Sims CR, Mastrobattista JM, et al. Milk-alkali syndrome in pregnancy. Obstet Gynecol 2004; 104:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/15\">",
"      Lin SH, Lin YF, Cheema-Dhadli S, et al. Hypercalcaemia and metabolic alkalosis with betel nut chewing: emphasis on its integrative pathophysiology. Nephrol Dial Transplant 2002; 17:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/16\">",
"      Allen SE, Singh S, Robertson WG. The increased risk of urinary stone disease in betel quid chewers. Urol Res 2006; 34:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/17\">",
"      Kirsner, JB, Palmer, WL. Alkalosis complicating the Sippy treatment of peptic ulcer. Arch Intern Med 1942; 69:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/18\">",
"      Kapsner P, Langsdorf L, Marcus R, et al. Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med 1986; 146:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/19\">",
"      Bronner F. Mechanisms of intestinal calcium absorption. J Cell Biochem 2003; 88:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/20\">",
"      Felsenfeld AJ, Levine BS. Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol 2006; 1:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/21\">",
"      McMillan DE, Freeman RB. The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) 1965; 44:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/22\">",
"      Sutton RA, Wong NL, Dirks JH. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 1979; 15:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/23\">",
"      Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 2010; 21:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/24\">",
"      Adams ND, Gray RW, Lemann J Jr. The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 1979; 48:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/25\">",
"      Broadus AE, Insogna KL, Lang R, et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/26\">",
"      Dorsch TR. The milk-alkali syndrome, vitamin D, and parathyroid hormone. Ann Intern Med 1986; 105:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/27\">",
"      Abreo K, Adlakha A, Kilpatrick S, et al. The milk-alkali syndrome. A reversible form of acute renal failure. Arch Intern Med 1993; 153:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27094/abstract/28\">",
"      Ennen CS, Magann EF. Milk-alkali syndrome presenting as acute renal insufficiency during pregnancy. Obstet Gynecol 2006; 108:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 827 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-5866CBA7F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27094=[""].join("\n");
var outline_f26_29_27094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H69903561\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Modern presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69903827\">",
"      Extrarenal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69902863\">",
"      - Decreased bone buffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Possible role of calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69903789\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69902931\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69903554\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69903561\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27095="Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease";
var content_f26_29_27095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Nicholas S Hill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Naomi R Kramer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27095/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/29/27095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive ventilation refers to mechanical ventilation without the need for an invasive interface (ie, an invasive airway) between the ventilator and the patient. Noninvasive positive pressure ventilation (NPPV) is currently the preferred mode of noninvasive ventilation. Other modes that long antedated NPPV are used occasionally, including negative pressure ventilators and abdominal displacement ventilators. Diaphragm pacers and glossopharyngeal breathing are still used for special applications.",
"   </p>",
"   <p>",
"    This topic will discuss the different forms of noninvasive ventilation that are used for neuromuscular and chest wall disease, emphasizing the use of NPPV. The types and applications of noninvasive ventilatory support are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71141 \" href=\"UTD.htm?28/15/28924\">",
"     table 1",
"    </a>",
"    ). Practical aspects of implementing noninvasive nocturnal ventilatory support and daytime noninvasive ventilatory assistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONINVASIVE POSITIVE PRESSURE VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation has gained popularity over the past decade and is now the most commonly used mode of noninvasive ventilation in most hospitals. This ascendancy has been related to ease of application, portability, demonstrated efficacy, and the ability to eliminate obstructive sleep apneas that may be induced or potentiated by other noninvasive ventilators [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/1\">",
"     1",
"    </a>",
"    ]. NPPV requires an interface (ie, a mask or other device that directs airflow into the upper airway) and a positive pressure ventilator. In contrast to ventilation via an invasive airway, NPPV uses an open breathing circuit, is inherently leaky, and depends upon patient cooperation to achieve ventilatory assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three basic types of interfaces are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nasal masks (",
"      <a class=\"graphic graphic_picture graphicRef52499 \" href=\"UTD.htm?28/23/29055\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75445 \" href=\"UTD.htm?25/33/26143\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oronasal masks (",
"      <a class=\"graphic graphic_picture graphicRef76935 \" href=\"UTD.htm?40/31/41471\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68361 \" href=\"UTD.htm?38/27/39358\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mouthpieces (",
"      <a class=\"graphic graphic_picture graphicRef60750 \" href=\"UTD.htm?9/57/10142\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nasal masks are the most popular interface for chronic administration of NPPV in patients with neuromuscular disease or chest wall deformity. They provide greater patient comfort and better preservation of speech and swallowing than do other interfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several types of nasal masks are commonly used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard nasal masks are clear plastic dome-shaped devices that fit over the entire nose and have a soft rubber or silicone cuff to maintain an air seal. Numerous manufacturers (Fischer Paykel Inc, Wellington NZ, Resmed, Inc, San Diego, CA, and Respironics, Inc, Murrysville, PA) supply standard nasal masks in a variety of sizes, including pediatric sizes. Most patients successfully adapt to standard masks, but some are uncomfortable because of poor fit or excessive mask pressure on the skin that occasionally leads to nasal bridge ulcerations.",
"     </li>",
"     <li>",
"      Several types of \"gel masks\" that use a soft gel or foam in the sealing gasket or \"minimasks\" that seal only over the surface of the nose may enhance tolerance in patients having trouble adapting to standard nasal masks. Chin straps help to reduce small mouth leaks, but the resulting seal is usually not as effective as with an oronasal mask in patients with mouth leaks.",
"     </li>",
"     <li>",
"      Nasal \"pillows\" or \"seals\" consist of soft rubber cones that are inserted directly into the nostrils, thus exerting no pressure on the nasal bridge (",
"      <a class=\"graphic graphic_picture graphicRef75445 \" href=\"UTD.htm?25/33/26143\">",
"       picture 2",
"      </a>",
"      ). If skin integrity becomes a problem, it may be helpful to alternate between types of interfaces (if both seal well) in order to decrease irritation at any one site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oronasal masks are the interface most often used to administer NPPV to patients with acute respiratory failure. They are less well tolerated than nasal masks for therapy of chronic respiratory failure, because they cover both the nose and mouth and interfere with speech and swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/4\">",
"     4",
"    </a>",
"    ]. However, they may be better tolerated than nasal masks in some patients, and warrant a trial in those having difficulty achieving success with nasal masks, particularly if there are large mouth leaks.",
"   </p>",
"   <p>",
"    Mouthpiece ventilation has been used for decades at certain centers to successfully support patients with respiratory failure due to neuromuscular disease, even those who require almost continuous ventilatory support [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/5\">",
"     5",
"    </a>",
"    ]. Mounting the ventilator on a wheelchair and suspending the mouthpiece on a gooseneck stand allows the patient to remain mobile and simultaneously have access to positive pressure as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either volume- or pressure-limited ventilators may be used to deliver NPPV. The early reports on nasal NPPV used portable",
"    <strong>",
"     volume-limited",
"    </strong>",
"    ventilators, such as the LP 10 (Covidien, Inc) or PLV 100 and 102 (Respironics, Inc) (",
"    <a class=\"graphic graphic_picture graphicRef72495 \" href=\"UTD.htm?19/24/19840\">",
"     picture 6",
"    </a>",
"    ). Portable pressure-limited ventilators, sometimes referred to as bilevel positive airway pressure (BPAP) ventilators (eg, BiPAP",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Respironics, Inc and VPAP, Resmed, Inc), are now used more often (",
"    <a class=\"graphic graphic_picture graphicRef65408 \" href=\"UTD.htm?38/17/39188\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73882 \" href=\"UTD.htm?8/3/8240\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/6\">",
"     6",
"    </a>",
"    ]. The latter ventilators provide ventilatory modes that resemble pressure support ventilation on critical care ventilators [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/7\">",
"     7",
"    </a>",
"    ]. They have sensitive flow triggers for cycling between inspiratory and expiratory pressures, matching patient breathing efforts closely; most also provide a time-cycled backup mode.",
"   </p>",
"   <p>",
"    Portable pressure-limited ventilators have gained popularity for administration of home NPPV because of lower cost, greater portability, and often greater comfort compared to volume-limited ventilators. They are now used in the vast majority of applications. These devices lack sophisticated alarms or internal batteries and are best suited for patients requiring nocturnal assistance only, but can be used to provide continuous (day and night) ventilator support if needed.",
"   </p>",
"   <p>",
"    Another potential advantage of pressure-limited ventilation is its ability to maintain inspiratory airflow on a breath-by-breath basis to compensate for air leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, volume-limited ventilators are not able to make breath-to-breath adjustments; in order to compensate for air-leaks, tidal volume must be increased. However, the presence of large air leaks may also impair the ability of pressure-limited ventilators to sense patient inspiratory or expiratory flows, leading to asynchrony. The use of a back-up rate that approximates the patient's spontaneous breathing rate assures ventilator inspiratory triggering during large leaks, and all ventilators have a mechanism to terminate inspiration, either based on I:E ratio or a maximal inspiratory time.",
"   </p>",
"   <p>",
"    Many manufacturers of critical care ventilators have added \"NIV\" (noninvasive ventilation) modes as an option to render them more tolerant of air leaks, better at synchronizing with patients and less apt to trigger \"nuisance\" alarms than traditional modes on these ventilators. However, most NIV modes have not been fully tested in clinical situations, and many require additional adjustments to compensate adequately for large air leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have directly compared pressure- and volume-limited ventilators have found similar efficacies in terms of supporting gas exchange and patient adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In terms of patient satisfaction, volume-limited ventilators may induce more gastrointestinal side effects, whereas pressure-limited ventilators are generally perceived by patients as being more comfortable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proportional assist ventilation (PAV) is a newer ventilatory mode that has the capability of making within breath adjustments in flow delivery and generates an inspiratory pressure that is proportional to patient effort. Theoretically, it can synchronize better with patient respirations and enhance comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/2\">",
"     2",
"    </a>",
"    ]. However, evidence on its superiority to pressure support is conflicting, particularly in patients with neuromuscular disease. One randomized study of 44 patients with acute respiratory failure found greater comfort with PAV than pressure support ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/15\">",
"     15",
"    </a>",
"    ]. In a series of 15 patients with chronic respiratory failure due to neuromuscular disease, PAV resulted in less reduction of work of breathing and less comfort than pressure support ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/16\">",
"     16",
"    </a>",
"    ]. This latter finding illustrates a shortcoming of PAV; when neuromechanical uncoupling (eg, due to neuromuscular disease) limits the patient's ability to generate inspiratory flow, PAV may not provide adequate ventilatory assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEGATIVE PRESSURE VENTILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices for negative pressure ventilation work by producing an intermittent negative pressure around the thorax and abdomen. The negative pressure is transmitted across the chest wall and diaphragm thereby assisting inhalation and lung inflation. When the perithoracic pressure returns to atmospheric (or positive in some devices), passive elastic recoil then deflates the lungs. Negative pressure ventilators have several disadvantages compared to NPPV (eg, less portable, harder to apply, and apt to exacerbate obstructive sleep apnea), and are infrequently used.",
"   </p>",
"   <p>",
"    Major categories of negative pressure ventilators include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tank ventilators, such as the iron lung (",
"      <a class=\"graphic graphic_picture graphicRef61051 \" href=\"UTD.htm?26/39/27248\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wrap or \"raincoat\" ventilators, consisting of an impervious nylon jacket suspended over the chest wall and abdomen by a rigid plastic or metal cage (",
"      <a class=\"graphic graphic_picture graphicRef81452 \" href=\"UTD.htm?32/52/33615\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cuirass or \"shell\" ventilators, consisting of a rigid dome that fits over the chest wall and abdomen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last two devices must be connected to a vacuum pump for generation of intermittent negative pressure. The efficiency of these negative pressure ventilators is dependent on the surface area of the chest and abdomen to which the negative pressure is applied and is greatest with the tank ventilator and least with the cuirass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ABDOMINAL RESPIRATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal respirators use motion of the abdominal viscera to augment diaphragm excursion. Examples include the intermittent abdominal pressure ventilator (\"pneumobelt\") (",
"    <a class=\"graphic graphic_picture graphicRef65937 \" href=\"UTD.htm?29/25/30097\">",
"     picture 10",
"    </a>",
"    ) and the rocking bed (",
"    <a class=\"graphic graphic_picture graphicRef65219 \" href=\"UTD.htm?31/6/31840\">",
"     picture 11",
"    </a>",
"    ). Both the rocking bed and pneumobelt are particularly useful in patients with bilateral diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the relative ineffectiveness of both devices in patients with acute illness or abnormal body habitus limits their wider use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pneumobelt",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pneumobelt, an intermittent abdominal pressure ventilator, consists of a corset containing an inflatable rubber bladder held firmly against the anterior abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/19\">",
"     19",
"    </a>",
"    ]. The bladder is connected to a positive pressure ventilator; when inflated by the ventilator, the bladder compresses the abdominal viscera, forcing the diaphragm upward and actively assisting exhalation. As long as the patient is sitting at an angle of at least 30 degrees above the horizontal, gravity returns the viscera and diaphragm to their original positions when the bladder deflates, thereby assisting inhalation.",
"   </p>",
"   <p>",
"    Advantages of the pneumobelt include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ease of application",
"     </li>",
"     <li>",
"      Portability",
"     </li>",
"     <li>",
"      Freedom of the hands and face (most important)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A tendency to cause skin abrasions at points of contact",
"     </li>",
"     <li>",
"      The need for use in the sitting position",
"     </li>",
"     <li>",
"      Relative lack of efficacy during episodes of acute respiratory deterioration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pneumobelt is used much less often than in the past, but is still occasionally used as a daytime adjunct when NPPV is used nocturnally [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rocking bed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rocking bed consists of a bed frame and mattress, upon which the patient lies supine and rocks in an arc of approximately 40 degrees, with the fulcrum at hip level. When the head rocks down, the abdominal viscera and diaphragm slide cephalad, thereby assisting exhalation. When the feet rock down, caudad movement of the viscera and diaphragm assists inhalation. The main advantages of the rocking bed are comfort and ease of application, while disadvantages include bulkiness and lack of portability. Due to difficulty in obtaining and maintaining rocking beds, they are no longer in use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAPHRAGM PACERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragm pacers consist of radio receivers and phrenic electrodes surgically implanted in the supraclavicular area and stimulated by an external transmitter (Avery Laboratories, Commack, NY) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/21\">",
"     21",
"    </a>",
"    ]. Presently, diaphragm pacers are used mainly in children who have high cervical cord lesions or central hypoventilation but are unable to tolerate NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/22\">",
"     22",
"    </a>",
"    ]. Recipients must have intact phrenic nerves and diaphragm function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10934?source=see_link\">",
"     \"Diaphragmatic pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link\">",
"     \"Treatment of diaphragmatic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of diaphragm pacers include easy operation and portability. Disadvantages include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The need for a tracheostomy tube in most patients because of induction of obstructive sleep apnea.",
"     </li>",
"     <li>",
"      High cost",
"     </li>",
"     <li>",
"      A lack of alarms despite the possibility of sudden loss of function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disadvantages and the efficacy of NPPV in the same types of patients who are candidates for diaphragm pacers have limited their clinical use.",
"   </p>",
"   <p>",
"    An investigational approach, the diaphragm pacing stimulation (DPS) system, differs in that the electrodes are placed directly on the diaphragm based on endoscopic mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/24\">",
"     24",
"    </a>",
"    ]. This latter approach may permit pacing and enhance diaphragm function in patients with neuropathies or myopathies, although this has not yet been established.",
"   </p>",
"   <p>",
"    A multicenter prospective evaluation of the DPS system is being conducted in patients with amyotrophic lateral sclerosis (ALS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/25\">",
"     25",
"    </a>",
"    ]. As part of the larger study, the DPS system has been used in 38 patients with respiratory muscle weakness due to ALS. The investigators used a specific peri-operative protocol that included short acting anesthetic agents without neuromuscular blockers and tested the diaphragm pacer prior to the end of the procedure. They encountered no significant postoperative complications and hypothesized that the early use of the pacer helps to fully inflate the lungs prior to the end of surgery, thus decreasing postoperative atelectasis and improving lung compliance. The results of the longer trial will be needed to test this hypothesis and to determine whether the DPS system slows the deterioration of lung function or improves survival among patients with ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GLOSSOPHARYNGEAL BREATHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glossopharyngeal (GPB) or \"frog breathing\" is a technique learned spontaneously by or taught to patients with respiratory insufficiency due to respiratory muscle weakness or paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/26\">",
"     26",
"    </a>",
"    ]. The main users of glossopharyngeal breathing currently are post-polio patients, those with high cervical cord lesions, and others with neuromuscular diseases that spare the upper airway musculature.",
"   </p>",
"   <p>",
"    Some patients use GPB to become independent from mechanical ventilation for up to several hours at a time while awake. Others may use GPB to delay the need for mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/27\">",
"     27",
"    </a>",
"    ]. The upper airway and tongue musculature must be intact, as they are used for gulping maneuvers to inject 50 to 60 mL boluses of air into the lungs. Each \"gulp\" takes 0.5 seconds and is repeated 10 to 12 times to achieve a normal tidal volume. The intake of tidal volume is repeated 10 times per minute for a total volume of 5 to 6",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"   </p>",
"   <p>",
"    The technique can also be used to improve cough efficacy; repetitive gulps achieve an inspired volume of up to 2 to 2.5 L, in order to increase expiratory flows and assist with coughing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXPIRATORY AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary restriction due to neuromuscular disease or chest wall deformity often have low expiratory airflow because of both reduced inspiratory capacity and weakness of expiratory muscles. As a result, these individuals are unable to cough effectively and clear airway secretions, making them susceptible to respiratory failure following a respiratory infection. Maneuvers and devices that augment expiratory flow should be used to help clear secretions, avoiding the need for hospitalization and intubation (",
"    <a class=\"graphic graphic_table graphicRef71141 \" href=\"UTD.htm?28/15/28924\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manually assisted coughing (also known as \"quad\" coughing) is a useful technique to augment cough efficiency and secretion clearance. It consists of an abdominal thrust applied firmly but gently to the mid-epigastrium in time with a cough. Resembling a Heimlich maneuver, this technique is used in acute care hospitals for patients with weakened cough muscles and taught to family members and aides of patients at home with severe restrictive disease, to be used whenever the patient needs help in clearing secretions.",
"   </p>",
"   <p>",
"    A number of mechanical devices can also be used to enhance cough and secretion removal, including the cough in-exsufflator (CoughAssist, Respironics, Inc), high frequency intrapulmonary air pulses (Percussionator, Bird Products, Inc) and the high frequency chest wall oscillator (HFCWO) (Vest, Hill-Rom, Inc). These devices work by different mechanisms, and limited evidence suggests that each may be beneficial in the proper setting. In a brief, uncontrolled trial in 17 patients with neuromuscular disease, the cough in-exsufflator improved physiologic parameters including exhaled tidal volume and peak expiratory flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/30\">",
"     30",
"    </a>",
"    ]. Another study showed a very low hospitalization rate among patients with neuromuscular disease treated with a regimen using a combination of inspiratory assist devices, quad coughing, and the cough in-exsufflator [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/31\">",
"     31",
"    </a>",
"    ]. A 12 week, controlled trial of HFCWO in 46 patients with amyotrophic lateral sclerosis showed reduced breathlessness, but no slowing of deterioration in pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27095/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive ventilation refers to mechanical ventilation without the need for an invasive interface (ie, an invasive airway) between the ventilatory device and the patient. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninvasive positive pressure ventilation (NPPV), the most commonly used mode of noninvasive ventilation, requires an interface (ie, a mask or other device that directs airflow into the upper airway) and a positive pressure ventilator. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Noninvasive positive pressure ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three basic types of interfaces are nasal masks, oronasal masks, and mouthpieces. Nasal masks or nasal pillows are generally preferred in the chronic setting; they provide greater patient comfort and better preservation of speech and swallowing than do other interfaces (",
"      <a class=\"graphic graphic_picture graphicRef52499 \" href=\"UTD.htm?28/23/29055\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75445 \" href=\"UTD.htm?25/33/26143\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interfaces'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oronasal masks are the interface used most often in the hospital for noninvasive ventilation in patients with acute respiratory failure; however, they are less well tolerated for chronic use. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interfaces'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with neuromuscular or chest wall disease who only require nocturnal ventilatory assistance, portable pressure-limited ventilators are usually preferred over portable volume-limited ventilators, because of lower cost, better portability, and often greater comfort. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ventilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more severe respiratory insufficiency who require daytime in addition to nighttime ventilatory support, either pressure or volume cycled ventilators can be used. They have sensitive flow triggers for cycling between inspiratory and expiratory pressures and match patient breathing efforts closely; most also provide a time-cycled backup mode. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ventilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Devices for negative pressure ventilation produce an intermittent negative pressure around the thorax and abdomen. The negative pressure is transmitted across the chest wall and diaphragm thereby assisting inhalation and lung inflation. Negative pressure ventilators are infrequently used and have several disadvantages compared to NPPV; they are less portable, harder to apply, and often exacerbate obstructive sleep apnea. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Negative pressure ventilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal respirators (eg, Pneumobelt and rocking bed) use motion of the abdominal viscera to augment diaphragm excursion. The pneumobelt can only be used when the patient is sitting, and generally only when the patient is awake; use of the rocking bed is limited by lack of portability, lack of availability, and difficulties with maintenance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Abdominal respirators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diaphragm pacers consist of radio receivers and phrenic electrodes surgically implanted in the supraclavicular or diaphragmatic areas, which are stimulated by an external transmitter. Diaphragm pacers are used mainly in children who have cervical cord lesions or central hypoventilation but are unable to tolerate NPPV. Recipients must have intact phrenic nerves and diaphragm function. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diaphragm pacers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/1\">",
"      Hill NS, Redline S, Carskadon MA, et al. Sleep-disordered breathing in patients with Duchenne muscular dystrophy using negative pressure ventilators. Chest 1992; 102:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/2\">",
"      Hess DR. Noninvasive ventilation in neuromuscular disease: equipment and application. Respir Care 2006; 51:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/3\">",
"      Leger SS, Leger P. The art of interface. Tools for administering noninvasive ventilation. Med Klin (Munich) 1999; 94:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/4\">",
"      Navalesi P, Fanfulla F, Frigerio P, et al. Physiologic evaluation of noninvasive mechanical ventilation delivered with three types of masks in patients with chronic hypercapnic respiratory failure. Crit Care Med 2000; 28:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/5\">",
"      Bach JR, Alba AS, Saporito LR. Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users. Chest 1993; 103:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/6\">",
"      Lloyd-Owen SJ, Donaldson GC, Ambrosino N, et al. Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J 2005; 25:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/7\">",
"      Strumpf, DA, Carlisle, CC, Millman, RP, et al. An evaluation of the Respironics BiPAP bi-level CPAP device for delivery of assisted ventilation. Respir Care 1990; 35:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/8\">",
"      Mehta S, McCool FD, Hill NS. Leak compensation in positive pressure ventilators: a lung model study. Eur Respir J 2001; 17:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/9\">",
"      Ferreira JC, Chipman DW, Hill NS, Kacmarek RM. Bilevel vs ICU ventilators providing noninvasive ventilation: effect of system leaks: a COPD lung model comparison. Chest 2009; 136:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/10\">",
"      Restrick LJ, Fox NC, Braid G, et al. Comparison of nasal pressure support ventilation with nasal intermittent positive pressure ventilation in patients with nocturnal hypoventilation. Eur Respir J 1993; 6:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/11\">",
"      Chadda K, Clair B, Orlikowski D, et al. Pressure support versus assisted controlled noninvasive ventilation in neuromuscular disease. Neurocrit Care 2004; 1:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/12\">",
"      Mu&ntilde;oz X, Crespo A, Marti S, et al. Comparative study of two different modes of noninvasive home mechanical ventilation in chronic respiratory failure. Respir Med 2006; 100:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/13\">",
"      Windisch W, Storre JH, Sorichter S, Virchow JC Jr. Comparison of volume- and pressure-limited NPPV at night: a prospective randomized cross-over trial. Respir Med 2005; 99:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/14\">",
"      Vitacca M, Rubini F, Foglio K, et al. Non-invasive modalities of positive pressure ventilation improve the outcome of acute exacerbations in COLD patients. Intensive Care Med 1993; 19:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/15\">",
"      Gay PC, Hess DR, Hill NS. Noninvasive proportional assist ventilation for acute respiratory insufficiency. Comparison with pressure support ventilation. Am J Respir Crit Care Med 2001; 164:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/16\">",
"      Hart N, Hunt A, Polkey MI, et al. Comparison of proportional assist ventilation and pressure support ventilation in chronic respiratory failure due to neuromuscular and chest wall deformity. Thorax 2002; 57:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/17\">",
"      Hill NS. Clinical applications of body ventilators. Chest 1986; 90:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/18\">",
"      Abd AG, Braun NM, Baskin MI, et al. Diaphragmatic dysfunction after open heart surgery: treatment with a rocking bed. Ann Intern Med 1989; 111:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/19\">",
"      ADAMSON JP, LEWIS L, STEIN JD. Application of abdominal pressure for artificial respiration. J Am Med Assoc 1959; 169:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/20\">",
"      Bach JR, Penek J. Obstructive sleep apnea complicating negative-pressure ventilatory support in patients with chronic paralytic/restrictive ventilatory dysfunction. Chest 1991; 99:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/21\">",
"      Glenn WW, Brouillette RT, Dentz B, et al. Fundamental considerations in pacing of the diaphragm for chronic ventilatory insufficiency: a multi-center study. Pacing Clin Electrophysiol 1988; 11:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/22\">",
"      Moxham J, Shneerson JM. Diaphragmatic pacing. Am Rev Respir Dis 1993; 148:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/23\">",
"      Bach JR, O'Connor K. Electrophrenic ventilation: a different perspective. J Am Paraplegia Soc 1991; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/24\">",
"      Onders RP, Elmo MJ, Ignagni AR. Diaphragm pacing stimulation system for tetraplegia in individuals injured during childhood or adolescence. J Spinal Cord Med 2007; 30 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/25\">",
"      Onders RP, Carlin AM, Elmo M, et al. Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg 2009; 197:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/26\">",
"      DAIL CW, AFFELDT JE, COLLIER CR. Clinical aspects of glossopharyngeal breathing; report of use by one hundred postpoliomyelitic patients. J Am Med Assoc 1955; 158:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/27\">",
"      Bach JR, Bianchi C, Vidigal-Lopes M, et al. Lung inflation by glossopharyngeal breathing and \"air stacking\" in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2007; 86:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/28\">",
"      Bach JR. Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory aids. Chest 1994; 105:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/29\">",
"      Vianello A, Corrado A, Arcaro G, et al. Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections. Am J Phys Med Rehabil 2005; 84:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/30\">",
"      Fauroux B, Guillemot N, Aubertin G, et al. Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases. Chest 2008; 133:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/31\">",
"      Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997; 112:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27095/abstract/32\">",
"      Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology 2006; 67:991.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5114 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E9247BC0B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27095=[""].join("\n");
var outline_f26_29_27095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONINVASIVE POSITIVE PRESSURE VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interfaces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventilators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEGATIVE PRESSURE VENTILATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ABDOMINAL RESPIRATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pneumobelt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rocking bed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAPHRAGM PACERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GLOSSOPHARYNGEAL BREATHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXPIRATORY AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/5114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5114|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8240\" title=\"figure 1\">",
"      Respiratory support system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5114|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/23/29055\" title=\"picture 1\">",
"      Nasal CPAP masks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/33/26143\" title=\"picture 2\">",
"      Nasal pillows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/31/41471\" title=\"picture 3\">",
"      Oronasal mask",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/27/39358\" title=\"picture 4\">",
"      Orofacial mask",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/57/10142\" title=\"picture 5\">",
"      Bennett lipseal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/24/19840\" title=\"picture 6\">",
"      Portable ventilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39188\" title=\"picture 7\">",
"      Bilevel airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/39/27248\" title=\"picture 8\">",
"      Emerson iron lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/52/33615\" title=\"picture 9\">",
"      Poncho wrap ventilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30097\" title=\"picture 10\">",
"      Pneumobelt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/6/31840\" title=\"picture 11\">",
"      Rocking bed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5114|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/15/28924\" title=\"table 1\">",
"      Uses of noninvasive ventilation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10934?source=related_link\">",
"      Diaphragmatic pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27096="Diagnosis of the antiphospholipid syndrome";
var content_f26_29_27096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of the antiphospholipid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Doruk Erkan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27096/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27096/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/29/27096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is characterized by the occurrence of venous or arterial thrombosis or of specific pregnancy morbidity, in the presence of laboratory evidence of antiphospholipid antibodies (aPL). APS occurs either as a primary condition or in the setting of an underlying disease, usually systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    The presence of aPL, which are directed against phospholipid-binding plasma proteins, may be demonstrated directly by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enzyme linked immunosorbent assay (ELISA) testing in the case of anticardiolipin antibody and anti-&szlig;",
"      <sub>",
"       2",
"      </sub>",
"      -glycoprotein I antibody tests",
"     </li>",
"     <li>",
"      A confirmed clotting assay that demonstrates effects of an aPL on the phospholipid-dependent factors in the coagulation cascade (lupus anticoagulant test)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of the APS will be reviewed here. The pathogenesis, clinical manifestations, and treatment of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical suspicion for APS should be raised in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occurrence of one or more otherwise unexplained thrombotic or thromboembolic events (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      One or more specific adverse outcomes related to pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"       \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Otherwise unexplained thrombocytopenia or prolongation of a test of blood coagulation (eg, activated partial thromboplastin time, aPTT) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Hematologic manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'The antibodies'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients suspected of APS or in those in whom there is uncertainty regarding the cause of a clinical event that may be related to APS, we perform a thorough medical history, physical examination, and selected laboratory testing, which are necessary to make the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/1\">",
"     1",
"    </a>",
"    ]. We generally do not test for aPL in patients at low risk of APS, such as elderly patients who present with thromboembolism and have other risk factors for such events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60490084\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be focused on the nature and frequency of thromboembolic events, the outcomes of pregnancies in female patients, and other risk factors for thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Medications'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H179909\">",
"     'Presence of aPL with no clinical events'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A review of systems should allow an associated illness to be suspected or excluded. The most important is systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Autoimmune and rheumatic diseases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60490091\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no pathognomonic physical findings of APS; however, abnormal features may be found on examinations that are related to ischemia or infarction of the skin, viscera, or nervous system. Physical examination findings may include livedo reticularis (and particularly livedo racemosa) (",
"    <a class=\"graphic graphic_picture graphicRef67495 \" href=\"UTD.htm?41/27/42418\">",
"     picture 1",
"    </a>",
"    ), digital ischemia, gangrene, deep venous thrombosis, or neurological lesions consistent with a stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60490098\">",
"    <span class=\"h2\">",
"     Initial laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain the following laboratory tests in the initial diagnostic evaluation for APS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG and IgM anticardiolipin antibodies (aCL) by enzyme-linked immunosorbent assay (ELISA)",
"     </li>",
"     <li>",
"      IgG and IgM anti-&szlig;",
"      <sub>",
"       2",
"      </sub>",
"      -glycoprotein I (anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI) antibodies by ELISA. Alternatively, some experts prefer to perform testing for anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI antibodies only in patients suspected of APS in whom the IgG and IgM aCL and lupus anticoagulant testing are negative.",
"     </li>",
"     <li>",
"      Lupus anticoagulant testing (dilute Russell viper venom time and activated partial thromboplastin time or another combination as the initial screening tests followed by the mixing study and confirmatory test) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Lupus anticoagulant'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H614382228\">",
"    <span class=\"h2\">",
"     Additional laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We also suggest additional testing as described below when evaluating a patient for the diagnosis of APS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmatory aPL testing &mdash; In patients with initial positive testing for aPL, the test should be repeated after at least 12 weeks to confirm persistence of the aCL, anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI, or LA test. Transiently elevated levels of IgG or IgM aCL, as well as a positive LA test, can occur in otherwise normal individuals and in the setting of viral or other infections. Confirmatory testing is required to satisfy the laboratory criteria for APS. (See",
"      <a class=\"local\" href=\"#H178994\">",
"       'Diagnosis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The need for confirmatory testing is supported by the finding that transient elevations in aPL are common. In one study of 522 randomly selected normal blood donors, the prevalence of IgG and IgM aCL on a first test was 6.5 and 9.4 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/4\">",
"       4",
"      </a>",
"      ]. However, repeatedly positive tests, which are required to meet the criteria for APS, were present in only 22 and 14 percent of those with an initial positive test (ie, 1.4 and 1.3 percent of the total population) after nine months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In patients with a strongly suggestive clinical history whose initial test result is a positive LA or a high titer aCL (&gt;40) or anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI, but whose second test is negative, we perform a third test after several weeks and use the third result to help guide decision-making. We consider the result negative and do not perform a third test if the first test was a minimally positive aCL or anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI and the second test was negative. Testing should be repeated if the patient has a clinical event.",
"     </li>",
"     <li>",
"      Testing for additional aPL &mdash; In case of strong clinical suspicion of APS and negative aPL tests discussed above (IgG and IgM aCL and anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI, and testing for LA), IgA aCL or IgA anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI may occasionally be positive [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3,5\">",
"       3,5",
"      </a>",
"      ]. We do not advise the routine clinical use of &ldquo;non-criteria&rdquo; aPL tests (eg, antibodies directed against prothrombin, phosphatidylserine or phosphatidylinositol, and prothrombin) because these tests are not well standardized and little is known about the sensitivity, specificity, and clinical as well as prognostic significance of testing for these antibodies.",
"      <br/>",
"      <br/>",
"      In patients with thrombosis in whom the initial aPL tests are all negative, both a false-negative result and an alternative diagnosis are considerations. However, patients with clinical features consistent with APS who do not have detectable aCL, anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI antibodies, or a positive LA test are rare, especially at the time of thrombosis.",
"     </li>",
"     <li>",
"      Testing for heritable and acquired thrombophilias &mdash; We recommend screening for heritable and acquired thrombophilic disorders (eg, factor V Leiden or protein C deficiency) in patients with venous thrombosis. In patients with negative initial aPL testing, such testing may identify an alternative diagnosis; in patients with positive aPL testing, the presence of additional risk factors for thrombophilia is useful for the identification of patients at elevated risk of thrombosis over that which occurs with aPL alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178994\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We diagnose the APS in patients who meet the revised Sapporo classification criteria (also called the Sydney criteria) for definite APS. Although the APS classification criteria were originally developed for research purposes, they can also be used in clinical practice to prevent &ldquo;over-diagnosis&rdquo; of APS. The criteria, developed by consensus among international clinical and laboratory experts on aPL and APS, were originally referred to in 1999 as the Sapporo criteria, and were subsequently modified at a workshop conducted by this group in Sydney in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These criteria have some limitations when used for diagnosis. (See",
"    <a class=\"local\" href=\"#H179338\">",
"     'Limitations of the revised Sapporo classification criteria for APS diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    According to the revised Sapporo criteria, definite APS is considered if at least one of the following clinical criteria",
"    <strong>",
"     and",
"    </strong>",
"    at least one of the following laboratory criteria are satisfied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical &mdash; The presence of either vascular thrombosis",
"      <strong>",
"       or",
"      </strong>",
"      pregnancy morbidity, defined as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vascular thrombosis is defined as one or more episodes of venous, arterial, or small vessel thrombosis, with unequivocal imaging or histologic evidence of thrombosis in any tissue or organ. Superficial venous thrombosis does",
"      <strong>",
"       not",
"      </strong>",
"      satisfy the criteria for thrombosis for APS.",
"     </li>",
"     <li>",
"      Pregnancy morbidity is defined as otherwise unexplained fetal death at &ge;10 weeks gestation of a morphologically normal fetus,",
"      <strong>",
"       or",
"      </strong>",
"      one or more premature births before 34 weeks of gestation because of eclampsia, preeclampsia, or placental insufficiency,",
"      <strong>",
"       or",
"      </strong>",
"      three or more embryonic (&lt;10 week gestation) pregnancy losses unexplained by maternal or paternal chromosomal abnormalities or by maternal anatomic or hormonal causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory &mdash; The presence of aPL, on two or more occasions at least 12 weeks apart and no more than five years prior to clinical manifestations, as demonstrated by one or more of the following [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IgG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM aCL in moderate or high titer (&gt;40 units GPL or MPL or &gt;99th percentile for the testing laboratory)",
"     </li>",
"     <li>",
"      Antibodies to &szlig;",
"      <sub>",
"       2",
"      </sub>",
"      -glycoprotein I (anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI) of IgG or IgM isotype at a titer &gt;99th percentile for the testing laboratory when tested according to recommended procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3,8\">",
"       3,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lupus anticoagulant (LA) activity detected according to published guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/2,9\">",
"       2,9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with thrombotic events, aPL, and other thrombotic risk factors, causality of the aPL cannot always be assumed with certainty, but patients can be diagnosed with APS if they fulfill the revised Sapporo criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"     7",
"    </a>",
"    ]. In one study, suggesting the nonspecificity of positive aPL testing, of 65 patients with a first venous thromboembolic (VTE) event and 179 patients with a suspected event who did not have a documented thrombus, the prevalence of IgG aCL was similar in the two groups (14 versus 18 percent at &gt;30 GPL units and 6.2 versus 3.4 percent at &gt;50 GPL units) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/10\">",
"     10",
"    </a>",
"    ]. An important limitation of the study was that testing for aPL was performed at one time point only, without confirmation by subsequent testing. LA activity, unlike aCL testing, was much more common in the patients with venous thromboembolism (14 versus 1.7 percent).",
"   </p>",
"   <p>",
"    The risk of thromboembolic phenomena and thus confidence in the diagnosis may increase with the level of aPL and with the number of different aPL tests present in a particular person. This was illustrated in a case-control study of 208 patients suspected of having APS and an equal number of age and gender matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/11\">",
"     11",
"    </a>",
"    ]. Each 10 U increase in IgM or IgG aCL was associated with a 5 to 7 percent increase in risk of thromboembolism. Furthermore, each additional aPL specificity (eg, aCL alone versus aCL plus LA versus aCL plus LA plus anti-&beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI) was associated with a 50 to 70 percent increase in the odds of arterial or venous thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87162868\">",
"    <span class=\"h2\">",
"     Additional risk factors for thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised Sapporo criteria also indicate that patients should be classified according to the presence or absence of additional risk factors for thrombosis. Such classification provides additional information that may be useful for research and for treatment, but does not alter the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179338\">",
"    <span class=\"h2\">",
"     Limitations of the revised Sapporo classification criteria for APS diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who appear clinically to have the APS may not meet the modified criteria, although these criteria help define a homogeneous population for research studies. Two evaluations of the proposed and revised Sapporo criteria have been conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In a retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/12\">",
"     12",
"    </a>",
"    ] of 200 aPL-positive patients who met the 1999 Sapporo criteria, only 59 percent met the 2006 revised criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional evaluations of the reliability and discriminatory testing of the revised Sapporo criteria are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66269800\">",
"    <span class=\"h2\">",
"     Diagnosis in patients not meeting criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing and cautious clinical and laboratory reassessment, based upon the clinical severity and potential clinical risk of recurrent events, is required in individuals who do not meet diagnostic criteria for APS, particularly in patients with other &ldquo;non-criteria&rdquo; clinical or laboratory manifestations associated with but not specific for APS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. These findings are listed below and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-criteria clinical findings associated with antiphospholipid antibodies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart valve disease",
"     </li>",
"     <li>",
"      Livedo reticularis",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Nephropathy",
"     </li>",
"     <li>",
"      Neurological manifestations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-criteria laboratory findings that may be associated with APS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG or IgM aCL or anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI levels in the range of 20 to 39 GPL or MPL units",
"     </li>",
"     <li>",
"      IgA aCL and IgA anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI",
"     </li>",
"     <li>",
"      Antiphosphatidylserine and antiphosphatidylethanolamine antibodies",
"     </li>",
"     <li>",
"      Antiprothrombin antibodies and antibodies to the phosphatidylserine-prothrombin complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624640928\">",
"    <span class=\"h2\">",
"     Catastrophic APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A very small subset of patients with APS has widespread thrombotic disease with multiorgan failure, termed \"catastrophic APS.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Catastrophic APS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary criteria proposed for classification purposes have been validated (",
"    <a class=\"graphic graphic_table graphicRef62724 \" href=\"UTD.htm?35/51/36667\">",
"     table 1",
"    </a>",
"    ). Additional diagnostic algorithms have been proposed to facilitate early recognition of catastrophic APS (",
"    <a class=\"graphic graphic_algorithm graphicRef75604 graphicRef66464 \" href=\"UTD.htm?26/41/27282\">",
"     algorithm 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/14\">",
"     14",
"    </a>",
"    ]. We use these criteria for the diagnosis of catastrophic APS. The important steps in the proposed algorithms include assessment of the presence or absence, respectively, of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of APS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aPL",
"     </li>",
"     <li>",
"      Three or more new organ thromboses within a week",
"     </li>",
"     <li>",
"      Biopsy confirmation of a microthrombus",
"     </li>",
"     <li>",
"      Exclusion of other causes of multiple organ thromboses or microthromboses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSAYS FOR ANTIPHOSPHOLIPID ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of aPL may be demonstrated directly by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ELISA testing to identify aCL and anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI",
"     </li>",
"     <li>",
"      Clotting assay that demonstrates effects of an aPL on the phospholipid-dependent factors in the coagulation cascade (LA test)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A history of a biologic false positive serologic test for syphilis (BFPTS) may be a clue to the presence of any type of aPL: aCL, anti-&beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI antibodies, or an LA. However, because of the nonspecific nature of the BFPTS, the presence of one or more aPL should be confirmed with one of the tests indicated below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3,15-17\">",
"     3,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The full clinical and prognostic significance of other autoantibodies, including those directed against prothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/18\">",
"     18",
"    </a>",
"    ]. Testing is not routinely performed for these antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     aCL and anti-&beta;2GPI assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;&beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI is the main antigenic target of aPL detected in aCL and anti- &beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI assays. Some laboratories detect antibodies in immunoassays using other phospholipids. In the case of other anionic phospholipids, these antibodies may be binding to &beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI, to other phospholipid-binding proteins, or possibly to the phospholipids directly. However, assays for such antibodies are not presently useful in clinical practice.",
"   </p>",
"   <p>",
"    Antibody levels for aCL of IgG and IgM type are reported in units as GPL and MPL, respectively. Recommendations for a standard approach to testing and reporting were published in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lupus anticoagulant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lupus anticoagulant phenomenon refers to the ability of aPL to cause prolongation of in vitro clotting assays such as the activated partial thromboplastin time (aPTT), the dilute Russell viper venom time (dRVVT), the kaolin clotting time, or, infrequently, the prothrombin time. This prolongation is not reversed when the patient's plasma is diluted 1:1 with normal platelet-free plasma. In contrast, such mixing studies do correct the clotting abnormality associated with factor deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical use of coagulation tests\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One common effect of aPL detected by routine laboratory testing is the prolongation of the aPTT. However, only about one-half of patients with LAs have prolongations of the aPTT. Thus, if APS is suspected strongly, additional testing, usually with a dRVVT, is essential.",
"   </p>",
"   <p>",
"    In 2009, an international committee recommended the following updated guidelines for the detection of LAs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/2\">",
"     2",
"    </a>",
"    ]; an additional explanation of technical details can be found in an excellent review [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood should be collected before initiation of an anticoagulant medication in 0.109 M sodium citrate 9:1.",
"     </li>",
"     <li>",
"      Both patient and normal plasma should be as platelet-free as possible. For testing on fresh plasma, frozen samples, and pooled normal plasma, the platelet count should be less than",
"      <span class=\"nowrap\">",
"       10,000/microL.",
"      </span>",
"      Platelet filtration, the preferred method for preparing platelet-free plasma, may interfere with testing of other coagulation factors.",
"     </li>",
"     <li>",
"      Two or more tests should be used to screen for LAs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/2\">",
"       2",
"      </a>",
"      ]. The most commonly used assays are the dRVVT and the dilute activated PTT (dAPTT). Other tests include the kaolin clotting time (KCT) and the dilute prothrombin time (dPT) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/3\">",
"       3",
"      </a>",
"      ]. An LA is present if any of the tests is positive [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibitor activity should be documented by the effect of patient plasma on pooled normal plasma. Confirmatory studies need to be performed to document the phospholipid dependence of the inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory experience is important in LA assays. In one study, one quarter of all plasma samples diagnosed as having LA activity were found to be false-positive tests upon measurement in a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Detection of aPL during anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have been started on anticoagulation but require confirmation of initial positive aPL testing, we prefer the use of aCL and anti-&beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI antibodies, which are unaffected by anticoagulation. We rarely perform LA testing in anticoagulated patients, because of the risk of false-negative or positive results. The following issues guide testing and interpretation of LA in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , some experts believe that LA activity can be detected if the INR is &lt;3.5, while others believe that the LA test should not be ordered in anticoagulated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"       7",
"      </a>",
"      ]. In the setting of warfarin anticoagulation, the patient plasma is diluted 1:2 with normal plasma before testing. Other techniques to circumvent this problem include using paired phospholipid-dependent tests on undiluted index plasmas and using paired tests based on snake venoms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may interfere with LA detection, particularly if anti-factor Xa activity is over the therapeutic range [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/20,22\">",
"       20,22",
"      </a>",
"      ]. The likelihood of an effect may depend upon the low molecular weight heparin preparation used [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may cause false positive tests for LAs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of APS depends upon the presenting clinical manifestations. Many acquired and genetic disorders may result in pregnancy loss, thromboembolic disease, or both. Additionally, aPL may coexist with other conditions and have a synergistic effect on the development of clinical events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179961\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis varies depending upon the vascular bed involved: venous, arterial, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with venous thrombosis or pulmonary embolic disease alone, the differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inherited and acquired coagulation and anticoagulation factor disorders (eg, protein C and protein S deficiency, factor V Leiden deficiency)",
"     </li>",
"     <li>",
"      Defective clot lysis",
"     </li>",
"     <li>",
"      Cancer and myeloproliferative disorders",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions can be distinguished from aPL by the lack of initial positive testing for aPL or failure to confirm positive results after 12 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with only arterial involvement, the following disorders should be excluded by the medical history, physical examination, and other testing as required (see appropriate topic reviews):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atherosclerosis",
"     </li>",
"     <li>",
"      Embolic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Atrial fibrillation or, much less commonly, atrial myxoma",
"     </li>",
"     <li>",
"      Marked left ventricular dysfunction",
"     </li>",
"     <li>",
"      Endocarditis",
"     </li>",
"     <li>",
"      Cholesterol emboli",
"     </li>",
"     <li>",
"      Paradoxical embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decompression sickness (caisson disease)",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic-uremic",
"      </span>",
"      syndrome",
"     </li>",
"     <li>",
"      Polyarteritis nodosa and other forms of systemic vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions can be distinguished from aPL by the lack of initial positive testing for aPL or failure to confirm positive results after 12 weeks. (See",
"    <a class=\"local\" href=\"#H178994\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Complete testing for inherited thrombophilias is not justified in patients presenting only with arterial thrombosis, since these abnormalities usually result in venous, rather than arterial, thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APS with central nervous system manifestations can be difficult to distinguish from other diseases with white matter lesions such as multiple sclerosis or lupoid sclerosis. The presence of characteristic spinal fluid abnormalities can be helpful in diagnosing multiple sclerosis especially since the latter can have the presence of non-pathogenic aPL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link&amp;anchor=H23#H23\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\", section on 'Cranial neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Arterial and venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of arterial and venous thrombosis, either simultaneously or sequentially, suggests the following diseases, which are discussed elsewhere (see appropriate topic reviews):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia",
"     </li>",
"     <li>",
"      Defective clot lysis due to dysfibrinogenemia or plasminogen activator deficiency",
"     </li>",
"     <li>",
"      Homocysteinemia",
"     </li>",
"     <li>",
"      Myeloproliferative disorders, polycythemia vera (P vera), or paroxysmal nocturnal hemoglobinuria",
"     </li>",
"     <li>",
"      Hyperviscosity due to P vera, Waldenstrom's macroglobulinemia, sickle cell disease",
"     </li>",
"     <li>",
"      Systemic vasculitis, such as those associated with antineutrophil cytoplasmic antibodies",
"     </li>",
"     <li>",
"      Paradoxical embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory findings of aPL will be absent or not confirmed upon retesting in these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87162610\">",
"    <span class=\"h3\">",
"     Thrombotic microangiopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions may be difficult to distinguish from catastrophic APS because of the common occurrence of thrombotic microangiopathic disease affecting multiple organs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/14\">",
"     14",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/Hemolytic",
"      </span>",
"      uremic syndrome",
"      <span class=\"nowrap\">",
"       (TTP/HUS)",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HELLP syndrome (of hemolysis, elevated liver enzymes, and low platelets with pregnancy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sepsis with multiorgan failure and disseminated intravascular coagulation (DIC) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost half of the patients who develop catastrophic APS have not had a prior history of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27096/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, a high level of suspicion and testing for aPL are necessary in these clinical settings. Use of the criteria established for this disorder along with the diagnostic algorithms help to distinguish these conditions. (See",
"    <a class=\"local\" href=\"#H624640928\">",
"     'Catastrophic APS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other non-aPL risk factors for thrombosis, including postoperative status, features of other thrombotic microangiopathies, infection, DIC, or possible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia, suggest an alternative diagnosis to APS. However, in some patients (eg, with SLE,",
"    <span class=\"nowrap\">",
"     TTP/HUS,",
"    </span>",
"    and aPL), APS may overlap with other thrombotic disorders. Patients with catastrophic APS may have laboratory features such as elevated fibrin degradation products, depressed fibrinogen levels, or elevated D-dimer concentrations that are more typically found with disseminated intravascular coagulation (DIC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179909\">",
"    <span class=\"h2\">",
"     Presence of aPL with no clinical events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various aPL may be present in some people who are otherwise healthy, have autoimmune or rheumatic disease, and have been exposed to certain drugs or infectious agents. The presence of aPL alone, in the absence of a thrombotic event or pregnancy morbidity, is insufficient for diagnosis of the clinical syndrome of APS, as detailed above. Medications known to be associated with aPL production include the phenothiazines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . However, because these medications usually do not lead to the production of antibodies to &beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI, they are generally not associated with clinical events. These and other associations are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Prevalence in different conditions'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H178994\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179916\">",
"    <span class=\"h2\">",
"     Recurrent pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of recurrent pregnancy loss is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical suspicion for the antiphospholipid syndrome (APS) should be raised in the following scenarios (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Occurrence of one or more otherwise unexplained thrombotic or thromboembolic events",
"     </li>",
"     <li>",
"      One or more specific adverse outcomes related to pregnancy",
"     </li>",
"     <li>",
"      Otherwise unexplained thrombocytopenia or prolongation of a test of blood coagulation (eg, PT or aPTT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The APS is diagnosed by the presence of two major components, one clinical and the other a laboratory finding (see",
"      <a class=\"local\" href=\"#H178994\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least one clinical occurrence of either vascular thrombosis, other than superficial venous thrombosis, or one of several pregnancy morbidities, such as recurrent fetal loss",
"     </li>",
"     <li>",
"      Persistent presence in the serum of at least one type of antiphospholipid antibody (aPL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      aPL are directed against serum proteins bound to anionic phospholipids and may be detected by (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Assays for antiphospholipid antibodies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lupus anticoagulant testing",
"     </li>",
"     <li>",
"      Anticardiolipin antibody ELISA",
"     </li>",
"     <li>",
"      Anti-&szlig;",
"      <sub>",
"       2",
"      </sub>",
"      -glycoprotein I ELISA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test for lupus anticoagulant (LA) is a clotting assay (LA test) that demonstrates effects of these antibodies on the phospholipid-dependent factors in the coagulation cascade. The most common screening tests employed as the first step of a LA test are the activated partial thromboplastin time (aPTT), and the dilute Russell viper venom time. A prolonged screening test alone is not adequate for LA positivity; confirmatory steps with mixing studies (in order to rule out factor deficiencies) and additional phospholipid reagents (to demonstrate phospholipid dependence) are also required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lupus anticoagulant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of the APS is broad and includes venous or arterial thrombotic events or pregnancy morbidity due to other causes, and the presence of nonpathogenic aPL due to drugs or infection. Additionally, aPL may coexist with other conditions and have a synergistic effect on the development of clinical events. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179961\">",
"       'Thrombosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179909\">",
"       'Presence of aPL with no clinical events'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179916\">",
"       'Recurrent pregnancy loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/1\">",
"      Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/2\">",
"      Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/3\">",
"      Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/4\">",
"      Vila P, Hern&aacute;ndez MC, L&oacute;pez-Fern&aacute;ndez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/5\">",
"      Bertolaccini ML, Gomez S, Pareja JF, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/6\">",
"      Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/7\">",
"      Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/8\">",
"      Reber G, Tincani A, Sanmarco M, et al. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/9\">",
"      Wisl&oslash;ff F, Jacobsen EM, Liest&oslash;l S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/10\">",
"      Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86:3685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/11\">",
"      Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/12\">",
"      Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/13\">",
"      Bobba RS, Johnson SR, Davis AM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value? J Rheumatol 2007; 34:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/14\">",
"      Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/15\">",
"      Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other \"antiphospholipid\" autoantibodies. Blood 1994; 84:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/16\">",
"      Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/17\">",
"      Pierangeli SS, de Groot PG, Dlott J, et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011; 20:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/18\">",
"      Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 2010; 56:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/19\">",
"      Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations--a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/20\">",
"      Tripodi A. Testing for lupus anticoagulants: all that a clinician should know. Lupus 2009; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/21\">",
"      Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/22\">",
"      Liest&oslash;l S, Wisl&oslash;ff F. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thromb Res 2005; 115:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/23\">",
"      Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27096/abstract/24\">",
"      Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12:70.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4678 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27096=[""].join("\n");
var outline_f26_29_27096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60490084\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60490091\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60490098\">",
"      Initial laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H614382228\">",
"      Additional laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178994\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87162868\">",
"      Additional risk factors for thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179338\">",
"      Limitations of the revised Sapporo classification criteria for APS diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66269800\">",
"      Diagnosis in patients not meeting criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624640928\">",
"      Catastrophic APS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSAYS FOR ANTIPHOSPHOLIPID ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      aCL and anti-&beta;2GPI assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lupus anticoagulant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Detection of aPL during anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179961\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Arterial and venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87162610\">",
"      - Thrombotic microangiopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179909\">",
"      Presence of aPL with no clinical events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179916\">",
"      Recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4678|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/27/12734\" title=\"algorithm 1A\">",
"      Diagnosis of CAPS with APS or aPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/19/21808\" title=\"algorithm 1B\">",
"      Diagnosis of CAPS without history of APS or aPL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4678|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/27/42418\" title=\"picture 1\">",
"      Livedo reticularis in lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/51/36667\" title=\"table 1\">",
"      Catastrophic APS criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27097="Tachycardia-mediated cardiomyopathy";
var content_f26_29_27097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tachycardia-mediated cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27097/contributors\">",
"     Cynthia M Tracy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27097/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27097/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/29/27097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathies are a clinically heterogenous group of heart muscle disorders that are defined by the presence of abnormal myocardial structure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function in the absence of ischemic heart disease or abnormal loading conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They are classified according to the phenotype, eg, hypertrophic, dilated, arrhythmogenic right ventricular cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-standing tachycardia is well recognized for its potential to induce a dilated cardiomyopathy. The prognosis in patients with dilated cardiomyopathy is variable and dependent on the cause; importantly, there are some etiologies that may improve or resolve following treatment. One such cause is a tachycardia-mediated (or tachycardia-induced) cardiomyopathy, a relatively rare entity, though one that is readily treatable with a good prognosis in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/3\">",
"     3",
"    </a>",
"    ]. While the exact incidence of tachycardia-mediated cardiomyopathy remains unclear, an association between tachycardia and cardiomyopathy has been recognized for some time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Virtually every form of supraventricular tachyarrhythmia, including ectopic atrial tachycardia, nonparoxysmal junctional tachycardia, and atrial fibrillation (AF), has been associated with reversible left ventricular dysfunction or \"cardiomyopathy.\" The development of a cardiomyopathy has also been documented with ventricular tachyarrhythmias and frequent ventricular premature beats [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Frequent ventricular ectopy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common clinical problem is determining whether the tachycardia is the primary cause of the patient's cardiomyopathy, or if the tachycardia is secondary to a cardiomyopathy of different etiology. This topic will discuss tachycardia-mediated cardiomyopathy as a primary cause of cardiomyopathy. Arrhythmias occurring in the setting of a specific cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H1492612#H1492612\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Ventricular arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic tachycardia ultimately produces significant cardiac structural changes, with left ventricular dilatation and cellular morphologic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. However, the exact mechanism by which tachycardia produces these changes is not well defined. Many alterations in neurohumoral and cellular activation have been described and several factors probably contribute to the development of rate-related myocardial dysfunction. Although data supporting certain potential mechanisms are compelling, it remains unclear whether they play an etiologic role or if they arise as a consequence of tachycardia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Animal models",
"      </strong>",
"      &mdash; Animal models, initially developed in the general investigation of heart failure, have been studied extensively in the evaluation of tachycardia-mediated cardiomyopathy. Rapid pacing produces changes in animals that are similar to those observed in humans, including a marked depression of left ventricular ejection fraction (LVEF), elevated filling pressures, depressed cardiac output, and increased systemic vascular resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/12-14,16-20\">",
"       12-14,16-20",
"      </a>",
"      ]. These changes are generally reversible with cessation of the tachycardia, although in some cases LVEF may not return to baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Similar findings have been reported in an animal model following the delivery of ventricular premature beats in a bigeminal pattern for 12 weeks, which resulted in left ventricular dilatation and reduction in LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The morphologic and biochemical changes that result from a tachycardia-mediated cardiomyopathy also may produce electrophysiologic abnormalities. In a canine model, chronic tachycardia was associated with ventricular arrhythmias (including polymorphic ventricular tachycardia and sudden death) that result from a prolongation in repolarization [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Depletion of myocardial energy stores and myocardial ischemia",
"      </strong>",
"      &mdash; Studies in animal models have shown that persistent tachycardia depletes high-energy stores as evidenced by reduced myocardial levels of creatine, phosphocreatine, and adenosine triphosphate (ATP), and diminished activity of the Na-K-ATPase pump [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. These changes are probably due to alterations in cellular metabolism with mitochondrial injury and increased activity of Krebs cycle oxidative enzymes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/11,16\">",
"       11,16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Myocardial ischemia may play a role in the development of tachycardia-mediated cardiomyopathy. Similar depletions in high-energy stores are seen in ischemic models following vessel occlusion, situations where high energy stores are rapidly depleted and left ventricular dysfunction occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. High-energy stores return to normal within days after the ischemic insults. Tachycardia-mediated depletion of high-energy stores, which may be mediated in part by ischemia, is reversible and may explain the reversibility of this cardiomyopathy.",
"      <br/>",
"      <br/>",
"      Abnormalities in subendocardial to subepicardial flow ratios and impaired coronary flow have been found in tachycardia-mediated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/29-32\">",
"       29-32",
"      </a>",
"      ]. The impaired coronary blood flow occurs in association with elevation in cardiac filling pressures and impaired left ventricular diastolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/21,33\">",
"       21,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal calcium handling and beta adrenergic",
"      </strong>",
"      <strong>",
"       responsiveness",
"      </strong>",
"      &mdash; Abnormalities in both calcium channel activity and sarcoplasmic reticulum calcium transport may contribute to the myocardial dysfunction in tachycardia-mediated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/16,31\">",
"       16,31",
"      </a>",
"      ]. Diminished beta-adrenergic responsiveness has also been described and may be due to reduced myocyte beta-1 receptor density (downregulation) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The reduction in beta receptor density and responsiveness is independent of hemodynamic and neurohumoral factors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Oxidative stress and injury",
"      </strong>",
"      &mdash; In patients with atrial fibrillation and atrial dysfunction, there is histologic evidence of oxidative stress and injury in the atrial myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/36\">",
"       36",
"      </a>",
"      ]. This results in peroxynitrite formation, which modifies myofibrillar proteins, contributes to loss of fibrillar protein function, and alters myofibrillar energetics.",
"      <br/>",
"      <br/>",
"      Support for the role of oxidative stress comes from one animal study which found that the administration of the antioxidant vitamins E, C, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      attenuated the cardiac dysfunction and prevented beta receptor downregulation produced by rapid cardiac pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic",
"      </strong>",
"      <strong>",
"       basis",
"      </strong>",
"      <strong>",
"       and ACE gene",
"      </strong>",
"      <strong>",
"       polymorphism",
"      </strong>",
"      &mdash; An association has been reported between a gene polymorphism and tachycardia-mediated cardiomyopathy. Levels of angiotensin converting enzyme (ACE) are associated with a 287 base pair insertion",
"      <span class=\"nowrap\">",
"       (I)/deletion",
"      </span>",
"      (D) polymorphism in intron 16 of the ACE gene. The DD genotype is associated with increased serum ACE levels and a higher incidence of both ischemic and idiopathic dilated cardiomyopathy.",
"      <br/>",
"      <br/>",
"      The prevalence of ID and DD genotypes in 20 patients with tachycardia-mediated cardiomyopathy, 20 controls with persistent tachycardia but normal LV function, and 24 normal volunteers was compared [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/38\">",
"       38",
"      </a>",
"      ]. The DD genotype was significantly more common in the patients with tachycardia-mediated cardiomyopathy than in the other two groups. However, larger scale studies of this finding are required to further validate any role in association with tachycardia-mediated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS ASSOCIATED WITH TACHYCARDIA-MEDIATED CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of tachyarrhythmias have been associated with tachycardia-mediated cardiomyopathy, including atrial fibrillation, atrial flutter, ectopic atrial tachycardia, incessant atrioventricular nodal reentrant tachycardia, atrioventricular reciprocating tachycardia, and ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/10,39-53\">",
"     10,39-53",
"    </a>",
"    ]. Regardless of the arrhythmia, therapy to restore normal sinus rhythm or to slow the ventricular rate appears to result in an improvement in left ventricular function (",
"    <a class=\"graphic graphic_table graphicRef59233 \" href=\"UTD.htm?41/40/42635\">",
"     table 1",
"    </a>",
"    ). However, most descriptive series include only a small number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have shown that patients with atrial fibrillation (AF) are at increased risk for heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/54\">",
"     54",
"    </a>",
"    ]. In some patients, restoration of sinus rhythm or control of the rapid ventricular rate markedly improves or even normalizes the left ventricular ejection fraction (LVEF), indicating that the left ventricular dysfunction was primarily due to the rapid AF rather than an underlying dilated cardiomyopathy. Improvement in left ventricular function is seen with both rhythm and rate control, although it may be more likely with rhythm control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to ventricular dysfunction, the persistently elevated atrial rates in AF have been associated with an atrial myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/46\">",
"     46",
"    </a>",
"    ]. Evidence supports an association between atrial mechanical dysfunction in AF with altered intracellular calcium handling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incessant atrial tachycardia (AT), an infrequent cause of symptomatic supraventricular tachyarrhythmia, can cause myocardial dysfunction in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/55\">",
"     55",
"    </a>",
"    ]. Children are more likely than adults to present with tachycardia-induced cardiomyopathy due to incessant AT. When AT is seen in adults, it is more commonly associated with another cardiac problem and distinguishing the effect of tachycardia from that of the underlying cardiac disease may be difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H17173656#H17173656\">",
"     \"Focal atrial tachycardia\", section on 'Incessant AT resulting in cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16937?source=see_link&amp;anchor=H5913174#H5913174\">",
"     \"Atrial tachycardias in children\", section on 'Focal (ectopic) atrial tachycardia and atrial ectopic tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Incessant AT and ectopic AT have been associated with the development of cardiomyopathy that can be reversed with restoration of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/39-45\">",
"     39-45",
"    </a>",
"    ]. Fortunately, improved techniques for catheter ablation frequently permit definitive therapy for AT, which can lead to the resolution of myocardial dysfunction with a high degree of success [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/39,45,55\">",
"     39,45,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H9439996#H9439996\">",
"     \"Focal atrial tachycardia\", section on 'Treatment of incessant AT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"     \"Catheter ablation of atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reentrant supraventricular tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentrant supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reciprocating tachycardia (AVRT), are more commonly paroxysmal but can cause a persistent tachycardia. Cases of tachycardia-mediated cardiomyopathy have been described with persistent junctional reciprocating tachycardia, accessory pathway mediated tachycardia (ie, AVRT) and AVNRT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/43,47-50\">",
"     43,47-50",
"    </a>",
"    ]. In the absence of other factors, the cardiomyopathy related to incessant supraventricular tachycardia is reversible following catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only rare reports have described reversible cardiomyopathy related to ventricular tachycardia since this arrhythmia is usually associated with some form of underlying structural heart disease. However, idiopathic left ventricular tachycardia or right ventricular outflow tract ventricular tachycardia can arise in structurally normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/8,9,47\">",
"     8,9,47",
"    </a>",
"    ]. In rare cases, these arrhythmias are persistent or repetitive enough to result in a cardiomyopathy. Similar to supraventricular arrhythmias, the myopathy usually reverses following ablation of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Frequent ventricular ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very frequent ventricular ectopy in the form of ventricular premature beats has been associated with a reversible cardiomyopathy, even in the absence of sustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/10,56-59\">",
"     10,56-59",
"    </a>",
"    ]. This hypothesis is supported by a report of 27 patients treated with ablation for repetitive monomorphic ventricular ectopy (average of &gt;17,000 ectopic beats over 24 hours) originating from the right ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients with frequent nonsustained VT or a history of sustained VT were excluded. Eight of these patients had left ventricular ejection fraction (LVEF) &le;45 percent. Ablation was successful in seven of the eight patients with reduced LVEF, and left ventricular function improved in all seven of these patients (mean LVEF increased from 39 to 62 percent). Similar findings have been reported in a series of 42 patients with frequent ventricular ectopy originating from the left ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The QRS duration of ventricular premature beats (VPBs) appears to play a role in the development of cardiomyopathy, with wider QRS complexes more likely to result in cardiomyopathy with a lower overall burden of VPBs. Among a series of 294 consecutive patients with frequent VPBs who were referred for catheter ablation of the VPBs, 113 patients (38 percent) were diagnosed as having cardiomyopathy (defined as LVEF less than 50 percent) related to frequent VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/61\">",
"     61",
"    </a>",
"    ]. QRS duration was significantly greater in the group with VPB-related cardiomyopathy (164 versus 149 milliseconds in persons with normal LVEF).",
"   </p>",
"   <p>",
"    QRS duration and epicardial site of VPB origin also appear to be important predictors of LVEF improvement following catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 48 persons referred for VPB ablation who had more than 10 percent VPBs and LVEF less than 50 percent, mean QRS duration was significantly lower in persons with normalized LVEF following ablation (158 versus 173 milliseconds in persons without LVEF improvement) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/62\">",
"       62",
"      </a>",
"      ]. Greater QRS durations have also been associated with longer times to normalization of LV systolic function following ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 87 persons with LV systolic dysfunction related to frequent VPBs, among whom 75 patients (86 percent) had successful ablation measured by reduction to less than 20 percent of the initial VPB burden, epicardial VPB origin was the only predictor of delayed LV function recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recurrent arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the apparent normalization of cardiac function when a tachycardia has been terminated or rate controlled, ultrastructural abnormalities of the myocardium may persist. This was suggested by a study of 24 patients with tachycardia-mediated cardiomyopathy due to a variety of tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/53\">",
"     53",
"    </a>",
"    ]. All had NYHA class III or IV heart failure on original presentation (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ). Within six months of rate control or correction of the rhythm, left ventricular ejection fraction (LVEF) had improved or normalized and symptoms had abated in all patients. However, subsequent events suggested a persistent myocardial abnormality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In five patients, tachycardia recurred (all due to atrial fibrillation). Symptoms of heart failure recurred and LVEF declined at a mean of seven months from recurrence. In all five patients, renewed rate control eliminated heart failure symptoms and normalized LVEF within one to three months.",
"     </li>",
"     <li>",
"      Three patients (including one who had had recurrent atrial fibrillation) died suddenly and unexpectedly during follow-up, despite a normal or near-normal LVEF at last evaluation and NYHA class I functional status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results would suggest the need for ongoing research into the \"normalcy\" of normalized myocardial function in patients with a history of tachycardia-mediated cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2314329\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with suspected tachycardia-mediated cardiomyopathy includes a thorough history and physical examination, with appropriately selected tests to establish the diagnosis, assess acuity, severity and etiology (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"UTD.htm?21/9/21661\">",
"     table 3",
"    </a>",
"    ). Several professional societies have issued recommendations for the evaluation of patients with suspected heart failure or cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/2,64-66\">",
"     2,64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2430195\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of tachycardia-mediated cardiomyopathy is variable but usually involves symptoms of palpitations or congestive heart failure. Patients may present with palpitations related to the rapidity or irregularity of their arrhythmia. However, those with more rapid heart rates typically present with symptoms related to the inappropriate heart rate before enough time has elapsed to result in a cardiomyopathy. In contrast, patients without palpitations may have little or no awareness of the arrhythmia. While such patients without palpitations are occasionally discovered during a routine medical exam for other reasons, typically they present with fatigue, decreased exercise tolerance, or symptomatic congestive heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that patients with more rapid heart rates often present earlier with symptoms related to the tachycardia, some investigators have hypothesized that patients with atrial arrhythmias who subsequently develop tachycardia-mediated cardiomyopathy have slower overall heart rates than patients who do not develop tachycardia-mediated cardiomyopathy. Published reports in both adult and pediatric populations support this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study of 331 patients without prior structural heart disease who had undergone ablation for atrial tachycardia (AT), nine percent presented with evidence of tachycardia-mediated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients with a tachycardia-mediated cardiomyopathy were younger (mean age 39 versus 51 years), more frequently male (60 versus 38 percent), and had incessant or very frequent paroxysmal tachycardia (100 versus 20 percent). Patients with tachycardia-mediated cardiomyopathy had slower ventricular heart rates during tachycardia compared with patients who did not have tachycardia-mediated cardiomyopathy (120 versus 149 beats per minute). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H17173656#H17173656\">",
"       \"Focal atrial tachycardia\", section on 'Incessant AT resulting in cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 16 pediatric patients with focal AT, the site of AT origin was associated with heart rate and the development of tachycardia-mediated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients with AT arising from the atrial appendages (uncommon in adults but are seen relatively frequently during childhood) were more commonly male (88 versus 25 percent of patients with AT from other sites) and more likely to have a ventricular heart rate less than 120 beats per minute on presentation. Such patients with atrial appendage AT were also more likely to be asymptomatic at presentation (75 versus 25 percent) and to present with tachycardia-mediated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2430238\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once tachycardia-mediated cardiomyopathy is suspected, appropriately selected tests can help to establish the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"UTD.htm?21/9/21661\">",
"     table 3",
"    </a>",
"    ). All patients should have an electrocardiogram (ECG) to document the cardiac rhythm and ventricular heart rate. Whenever possible, obtaining prior ECGs can be extremely helpful to determine whether ambiguous P wave morphologies are related to the sinus node (as seen on prior tracings) versus an ectopic atrial focus. Heart rate over time should be continuously measured for 24 to 48 hours using inpatient telemetry or ambulatory (Holter) monitoring. Patients in whom there is minimal variability in their heart rate, or in whom the heart rate is continuously above 130 beats per minutes, are much more likely to have atrial tachycardia. Because of the potential reversible nature of tachycardia-mediated cardiomyopathy, if uncertainty persists regarding the cardiac rhythm, full invasive electrophysiologic studies should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H15492827#H15492827\">",
"     \"Focal atrial tachycardia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with suspected tachycardia-mediated cardiomyopathy should undergo transthoracic echocardiography to document left ventricular size and function, in particular left ventricular ejection fraction. While there are no absolute echocardiographic parameters that can distinguish tachycardia-mediated cardiomyopathy from other forms of dilated cardiomyopathy, in general, the LV end-diastolic dimension tends to be smaller in patients with tachycardia-mediated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with newly diagnosed heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathy require an assessment for genetic and other causes of left ventricular dysfunction and exclusion of significant underlying coronary artery disease (CAD). Decisions on the initial use of stress testing or coronary angiography should be made based on the presence or absence of symptoms suggestive of CAD and the individual patient's likelihood of CAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Detection of coronary artery disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2430257\">",
"    <span class=\"h1\">",
"     RESTORING SINUS RHYTHM VERSUS RATE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatments for a patient with heart failure and tachycardia-mediated cardiomyopathy are the same as those used in most other patients with heart failure (eg, ACE or ARB inhibitors, beta blockers, diuretics). However, because of the potential reversible nature of tachycardia-mediated cardiomyopathy, aggressive efforts should be made to achieve excellent ventricular heart rate control or to restore sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with atrial fibrillation (AF) or atrial flutter resulting in cardiomyopathy, rate control alone can be very effective at improving cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/69\">",
"     69",
"    </a>",
"    ]. In these patients, decisions regarding rate versus rhythm control are based on multiple clinical factors. Decisions regarding particular antiarrhythmics and AV nodal blocking agents would be the same as for management of the AF patient with depressed left ventricular ejection fraction (LVEF) of any etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link&amp;anchor=H2#H2\">",
"     \"Restoration of sinus rhythm in atrial flutter\", section on 'Indications for restoration of sinus rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For other forms of arrhythmias that can result in tachycardia-mediated cardiomyopathy, in general, restoration of sinus rhythm is the desired goal. Options for the restoration of sinus rhythm include electrical cardioversion, antiarrhythmic drugs, and catheter ablation of the arrhythmia. Often, atrial arrhythmias can be refractory to antiarrhythmics and AV nodal blocking agents may be required in high dosages to achieve appropriate heart rates. In patients with depressed LVEF, it is important to avoid agents that have a higher likelihood of proarrhythmia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ) or that could further depress LVEF (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ). If an ablation is performed, close follow-up is required even after successful ablation because of the tendency for cardiomyopathy to recur if tachycardia recurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H15#H15\">",
"     \"Focal atrial tachycardia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16937?source=see_link&amp;anchor=H5913234#H5913234\">",
"     \"Atrial tachycardias in children\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"     \"Catheter ablation of atrial tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On rare occasions when all efforts at ventricular rate control, restoration of sinus rhythm, and catheter ablation of the arrhythmia have been unsuccessful, ablation of the AV node with insertion of a permanent pacemaker may be considered. All other therapeutic options should be exhausted before considering this approach. For these patients, implantation of a biventricular pacing unit should also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=see_link\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2430284\">",
"    <span class=\"h1\">",
"     RISK FOR RECURRENT TACHYCARDIA-MEDIATED CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the restoration of sinus rhythm, or ventricular rate control of the presenting tachycardia, most patients will have significant improvement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    normalization of left ventricular ejection fraction (LVEF) over a period of months. As such, patients who have not experienced sudden cardiac arrest or a sustained ventricular arrhythmia, and whose LVEF has improved to 40 percent or greater, usually do not require implantation of an implantable cardioverter-defibrillator (ICD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whereas the initial cardiomyopathy may have taken months to develop, recurrent tachycardia can lead to an abrupt decline in LVEF. As such, close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography is essential. Although there is minimal data and no society guidelines regarding the frequency of monitoring in these patients, we monitor using clinic visits, echocardiography, and ambulatory monitoring every three to six months for up to one to two years following the initial clinical improvement. In some patients whose LVEF has normalized, the LV chamber may remain somewhat enlarged. If tachycardia-mediated cardiomyopathy recurs, these patients are at substantial risk for sudden death and ICD implantation should be contemplated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27097/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"       \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia-mediated (or tachycardia-induced) cardiomyopathy is a relatively rare cause of a dilated cardiomyopathy resulting from prolonged periods of rapid ventricular heart rates. Tachycardia-mediated cardiomyopathy often improves or resolves following treatment and is associated with a good prognosis in most patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic tachycardia ultimately produces significant structural changes in the heart, with impressive left ventricular dilatation and cellular morphologic changes leading to a cardiomyopathy. The precise mechanism(s) by which a chronic tachycardia produces these changes remain incompletely described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all tachyarrhythmias have been reported to cause tachycardia-mediated cardiomyopathy. In most cases, the myocardial dysfunction improves or normalizes following therapy to control the ventricular heart rate or to restore normal sinus rhythm. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Arrhythmias associated with tachycardia-mediated cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of tachycardia-mediated cardiomyopathy is variable but usually involves symptoms of palpitations or congestive heart failure. Patients may present with palpitations related to the rapidity or irregularity of their arrhythmia. Alternatively, patients without palpitations may have little or no awareness of the arrhythmia and typically present with fatigue, decreased exercise tolerance, or symptomatic congestive heart failure. (See",
"      <a class=\"local\" href=\"#H2430195\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once tachycardia-mediated cardiomyopathy is suspected, appropriately selected tests can help to establish the diagnosis (",
"      <a class=\"graphic graphic_table graphicRef51433 \" href=\"UTD.htm?21/9/21661\">",
"       table 3",
"      </a>",
"      ). All patients should undergo electrocardiography, cardiac monitoring for 24 to 48 hours, echocardiography, and an assessment for coronary artery disease and other causes of left ventricular dysfunction. (See",
"      <a class=\"local\" href=\"#H2430238\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial treatments for a patient with heart failure and tachycardia-mediated cardiomyopathy are the same as those used in most other patients with heart failure (eg, ACE or ARB inhibitors, beta blockers, diuretics). However, because of the potential reversible nature of tachycardia-mediated cardiomyopathy, aggressive efforts should be made to achieve excellent ventricular heart rate control or to restore sinus rhythm. Therapeutic options include AV nodal blocking medications for ventricular rate control and electrical cardioversion, antiarrhythmic drugs, and catheter ablation of the arrhythmia for the restoration of sinus rhythm. (See",
"      <a class=\"local\" href=\"#H2430257\">",
"       'Restoring sinus rhythm versus rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following ventricular rate control",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the restoration of sinus rhythm, most patients will have significant improvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      normalization of left ventricular ejection fraction (LVEF) over a period of months. However, whereas the initial cardiomyopathy may have taken months to years to develop, recurrent tachycardia can lead to an abrupt decline in LVEF. We monitor using clinic visits, echocardiography, and ambulatory monitoring every three to six months for up to one to two years following the initial clinical improvement. (See",
"      <a class=\"local\" href=\"#H2430284\">",
"       'Risk for recurrent tachycardia-mediated cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/1\">",
"      Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/2\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/3\">",
"      Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/4\">",
"      Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/5\">",
"      SHACHNOW N, SPELLMAN S, RUBIN I. Persistent supraventricular tachycardia; case report with review of literature. Circulation 1954; 10:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/6\">",
"      Engel TR, Bush CA, Schaal SF. Tachycardia-aggravated heart disease. Ann Intern Med 1974; 80:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/7\">",
"      Coleman HN 3rd, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/8\">",
"      Vijgen J, Hill P, Biblo LA, Carlson MD. Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia. J Cardiovasc Electrophysiol 1997; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/9\">",
"      Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of \"tachycardia induced cardiomyopathy\" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996; 19:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/10\">",
"      Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/11\">",
"      Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990; 259:H218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/12\">",
"      Howard RJ, Stopps TP, Moe GW, et al. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol 1988; 66:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/13\">",
"      Morgan DE, Tomlinson CW, Qayumi AK, et al. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol 1989; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/14\">",
"      Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991; 261:H308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/15\">",
"      Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995; 92:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/16\">",
"      O'Brien PJ, Ianuzzo CD, Moe GW, et al. Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. Can J Physiol Pharmacol 1990; 68:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/17\">",
"      Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994; 89:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/18\">",
"      Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986; 74:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/19\">",
"      Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987; 75:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/20\">",
"      Damiano RJ Jr, Tripp HF Jr, Asano T, et al. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1987; 94:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/21\">",
"      Yamamoto K, Burnett JC Jr, Meyer LM, et al. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol 1996; 271:R1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/22\">",
"      Huizar JF, Kaszala K, Potfay J, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol 2011; 4:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/23\">",
"      Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997; 30:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/24\">",
"      Moe GW, Montgomery C, Howard RJ, et al. Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 1993; 121:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/25\">",
"      Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268:H836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/26\">",
"      Spinale FG, Clayton C, Tanaka R, et al. Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1992; 24:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/27\">",
"      Kloner RA, DeBoer LW, Darsee JR, et al. Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci U S A 1981; 78:7152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/28\">",
"      Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol 1981; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/29\">",
"      Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/30\">",
"      Shannon RP, Komamura K, Shen YT, et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993; 265:H801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/31\">",
"      Perreault CL, Shannon RP, Komamura K, et al. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992; 89:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/32\">",
"      Tanaka R, Fulbright BM, Mukherjee R, et al. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993; 25:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/33\">",
"      Sasayama S, Asanoi H, Ishizaka S. Continuous measurement of the pressure-volume relationship in experimental heart failure produced by rapid ventricular pacing in conscious dogs. Eur Heart J 1992; 13 Suppl E:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/34\">",
"      Marzo KP, Frey MJ, Wilson JR, et al. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res 1991; 69:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/35\">",
"      Yonemochi H, Yasunaga S, Teshima Y, et al. Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress. Circulation 2000; 101:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/36\">",
"      Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/37\">",
"      Shite J, Qin F, Mao W, et al. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 2001; 38:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/38\">",
"      Deshmukh PM, Krishnamani R, Romanyshyn M, et al. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 2004; 13:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/39\">",
"      Chiladakis JA, Vassilikos VP, Maounis TN, et al. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol 1997; 20:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/40\">",
"      Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/41\">",
"      Gallagher JJ. Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol 1985; 6:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/42\">",
"      Bertil Olsson S, Blomstr&ouml;m P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol 1984; 53:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/43\">",
"      Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/44\">",
"      Rao PS, Najjar HN. Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy with antiarrhythmic drugs. Int J Cardiol 1987; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/45\">",
"      Gillette PC, Wampler DG, Garson A Jr, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol 1985; 6:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/46\">",
"      Sanders P, Morton JB, Kistler PM, et al. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 2003; 108:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/47\">",
"      Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/48\">",
"      Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/49\">",
"      Leman RB, Gillette PC, Zinner AJ. Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone. Am Heart J 1986; 112:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/50\">",
"      Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993; 126:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/51\">",
"      Grimm W, Menz V, Hoffmann J, Maisch B. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2001; 24:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/52\">",
"      Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/53\">",
"      Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004; 110:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/54\">",
"      Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/55\">",
"      Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009; 53:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/56\">",
"      Satish OS, Yeh KH, Wen MS, Wang CC. Premature ventricular contraction-induced concealed mechanical bradycardia and dilated cardiomyopathy:. J Cardiovasc Electrophysiol 2005; 16:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/57\">",
"      Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007; 4:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/58\">",
"      Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012; 9:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/59\">",
"      Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/60\">",
"      Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm 2011; 8:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/61\">",
"      Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012; 9:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/62\">",
"      Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/63\">",
"      Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm 2013; 10:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/64\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/65\">",
"      . Evaluation of patients for ventricular dysfunction and heart failure. J Card Fail 2006; 12:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/66\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/67\">",
"      Sakaguchi H, Miyazaki A, Yamamoto M, et al. Clinical characteristics of focal atrial tachycardias arising from the atrial appendages during childhood. Pacing Clin Electrophysiol 2011; 34:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/68\">",
"      Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008; 31:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/69\">",
"      Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/70\">",
"      Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27097/abstract/71\">",
"      Dandamudi G, Rampurwala AY, Mahenthiran J, et al. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm 2008; 5:1111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1062 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27097=[""].join("\n");
var outline_f26_29_27097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ARRHYTHMIAS ASSOCIATED WITH TACHYCARDIA-MEDIATED CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reentrant supraventricular tachycardias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Frequent ventricular ectopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recurrent arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2314329\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2430195\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2430238\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2430257\">",
"      RESTORING SINUS RHYTHM VERSUS RATE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2430284\">",
"      RISK FOR RECURRENT TACHYCARDIA-MEDIATED CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/40/42635\" title=\"table 1\">",
"      Tachy mediated CM treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21661\" title=\"table 3\">",
"      ACC AHA evaluation HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16937?source=related_link\">",
"      Atrial tachycardias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=related_link\">",
"      Cardiac resynchronization therapy in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=related_link\">",
"      Catheter ablation of atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27098="Cancer-related fatigue: Treatment";
var content_f26_29_27098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer-related fatigue: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Carmen P Escalante, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/29/27098/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/29/27098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common problem in cancer patients. The most important factors contributing to cancer-related fatigue are treatment with cytotoxic chemotherapy, biologic response modifiers, molecularly targeted therapy (particularly the small molecular tyrosine kinase inhibitors and the therapeutic monoclonal antibody [MoAb]",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) or radiation therapy (RT), anemia, pain, emotional distress, sleep disturbance, and poor nutrition. Cancer-related fatigue is particularly prevalent with multimodality or dose-intense treatment protocols, and in patients with metastatic disease.",
"   </p>",
"   <p>",
"    Cancer-related fatigue profoundly affects quality of life (QOL) of both patients and their families, including physical, psychosocial, and",
"    <span class=\"nowrap\">",
"     economic/occupational",
"    </span>",
"    aspects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Fatigue is routinely identified by patients as one of the most distressing symptoms associated with cancer and its treatment, yet it has been consistently underreported and overlooked as a potentially remediable cause of treatment-related morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/9\">",
"     9",
"    </a>",
"    ]. More recently, screening for and treatment of cancer-related fatigue has become a major focus of supportive care in oncology. Guidelines from expert groups recommend screening for cancer-related fatigue at the initial visit, at the time that advanced disease is diagnosed, and at all chemotherapy visits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Survivors or patients who have been taken off treatment should continue to be monitored because fatigue may persist beyond the time of active treatment.",
"   </p>",
"   <p>",
"    Here we will review the treatment of cancer-related fatigue. The prevalence of fatigue in patients with cancer, screening and assessment for fatigue in this population, and other functional problems in patients with cancer, including specific rehabilitation issues, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=see_link\">",
"     \"Various rehabilitation issues in patients treated for cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of cancer-related fatigue involves specific treatment for potentially reversible causes (ie, treating anemia or metabolic or endocrine abnormalities, as well as managing pain, insomnia, depression, or anxiety) and symptomatic measures when no obvious etiology or reversible cause can be identified. Nonspecific symptomatic treatment measures include education, counseling, and pharmacologic (eg, psychostimulants) as well as nonpharmacologic (eg, exercise, yoga, acupuncture) measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606308092\">",
"    <span class=\"h2\">",
"     Control of physical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical symptoms such as nausea, dyspnea, and pain may be associated with fatigue, particularly in patients with advanced cancer. Optimizing management of these physical symptoms may significantly alleviate fatigue. The benefits of systematic monitoring and treatment of physical symptoms in fatigued patients was shown in a randomized trial in which 152 fatigued patients (fatigue score &ge;4 on a numerical rating scale of 1 to 10) with advanced cancer were randomly assigned to protocolized patient-tailored treatment or usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/11\">",
"     11",
"    </a>",
"    ]. The intervention group consisted of four meetings over a 10 week period with a nurse specialist who coordinated a complex intervention aimed at identifying and treating symptoms of pain, nausea, vomiting, constipation, lack of appetite, shortness of breath, cough, and dry mouth. There were modest but significant improvements over time in favor of the nurse-led intervention for the primary outcome (general fatigue, as assessed by the Multidimensional Fatigue Inventory) as well as for secondary outcomes such as level of reduced activity, symptom burden, interference of fatigue with daily life, anxiety, and intensity of fatigue as measured by the 0 to 10 numerical rating scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Management of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is the most common reversible cause of cancer-related fatigue, particularly among patients receiving chemotherapy. Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, iron,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , or vitamin B12 deficiency). If a potentially treatable cause cannot be identified, treatment options include red blood cell (RBC) transfusion, or for patients with chemotherapy-related myelosuppression, an erythropoietin stimulating agent (ESA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10231168\">",
"    <span class=\"h3\">",
"     Transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusions of packed red blood cells can improve fatigue due to anemia, although higher-quality studies are needed to determine which patients are most likely to respond, which are not, and the duration of any response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, for those patients requiring repeated transfusions, there are potential harms, including blood-borne infection, acute transfusion reaction, transfusion-associated graft-versus-host disease, subtle immune modulation, and iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"     \"Transfusion reactions caused by chemical and physical agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     ESAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of ESAs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    ) was initially established in anemic patients with chronic renal failure on dialysis. These agents have been extensively evaluated in cancer patients. While numerous randomized trials demonstrate that ESAs decrease the frequency of RBC transfusion in patients receiving chemotherapy for a nonmyeloid cancer, their impact on fatigue has been more difficult to demonstrate due to the direct mediating effect of hemoglobin levels and the confounding effect of transfusions. However, the available data suggest that ESAs modestly improve symptoms of fatigue in anemic patients receiving chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of ten studies evaluating epoetin in anemic patients receiving chemotherapy, epoetin was significantly superior to placebo for improvement of fatigue (standardized mean difference [SMD] in fatigue score -0.30, 95% CI -0.46 to -0.29) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/13\">",
"       13",
"      </a>",
"      ]. Four trials of darbepoetin in anemic cancer patients (three chemotherapy-related, one not chemotherapy-related) showed a borderline statistically significant improvement in fatigue score relative to placebo (SMD in fatigue score -0.13, 95% CI -0.27 to 0.00, p = 0.05).",
"     </li>",
"     <li>",
"      The impact of darbepoetin on cancer-related fatigue was further addressed in a compilation of data from the three placebo-controlled trials of patients receiving chemotherapy for lung cancer (two trials, 595 and 314 patients each) or a lymphoproliferative malignancy (one trial, 349 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/14\">",
"       14",
"      </a>",
"      ]. Fatigue was measured using the FACT-F scale.",
"     </li>",
"     <li>",
"      In a preliminary report, controlling for transfusions, patients receiving darbepoetin had significantly higher hemoglobin levels, and higher hemoglobin levels were associated with significantly less fatigue. Using latent growth modeling (which allows for simultaneous examination of direct and indirect effects by incorporating data from all time points), the mean decrease in the patient-reported FACT-F score with use of darbepoetin in the two lung cancer trials was 2.3 and 2.9 points, respectively. Neither value met or exceeded the predefined threshold for \"minimally important difference\" of 3 points. In contrast, for patients treated with darbepoetin for a lymphoproliferative malignancy, the mean decrease in the fatigue score was 3.5 points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until recently, ESAs were heavily promoted and utilized in cancer patients who had fatigue and any degree of anemia, whether related to chemotherapy or not. However, use of these agents has become controversial, particularly in patients with anemia unrelated to chemotherapy and in those receiving myelosuppressive chemotherapy with the intent of cure, because of concerns about thromboembolic side effects, higher mortality rates, and the possibility of adverse cancer outcomes.",
"   </p>",
"   <p>",
"    At least eight trials have shown inferior survival, worse locoregional tumor control,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased risk of thromboemboli in solid tumor patients treated with ESAs. In all eight, ESA dosing was targeted to achieve and maintain hemoglobin levels in excess of current recommendations (&ge;12",
"    <span class=\"nowrap\">",
"     g/dL);",
"    </span>",
"    in four, patients were receiving adjuvant or neoadjuvant chemotherapy for a potentially curable cancer, and in three, ESAs were administered to patients not receiving chemotherapy. These data led the US Food and Drug Administration to mandate labeling changes for ESAs that state that they are not indicated in patients with non-chemotherapy-related anemia or for those receiving myelosuppressive chemotherapy when the anticipated outcome is cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Effect on disease control and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of shortened survival and inferior tumor control have neither been excluded nor confirmed when ESAs are dosed to a target hemoglobin &lt;12",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    the level supported by",
"    <span class=\"nowrap\">",
"     ASCO/ASH",
"    </span>",
"    and NCCN guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Nevertheless, all three groups recommend that ESAs",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for cancer patients with anemia not associated with chemotherapy, that ESAs not be instituted unless the hemoglobin level is &le;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and that target hemoglobin levels not exceed 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H21#H21\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'ASH/ASCO guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the three groups has revised their guidelines to restrict use of ESAs to patients receiving palliative rather than potentially curative chemotherapy. However, the European Medicines Agency recommends that blood transfusions are preferred over ESAs in patients with chemotherapy-related anemia and a reasonably long life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/16\">",
"     16",
"    </a>",
"    ]. Controversies surrounding the use of ESAs in patients with solid tumors, and a comparison of the risks and benefits of ESAs versus transfusion (",
"    <a class=\"graphic graphic_table graphicRef78476 \" href=\"UTD.htm?31/32/32267\">",
"     table 1",
"    </a>",
"    ) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The above data relate to patients being treated for a nonmyeloid malignancy. The use of ESAs in patients with hematologic neoplasms is more complex. Although thromboembolic events and adverse cancer outcomes have not been reported, there is less evidence to support benefit from ESAs, responsiveness of the bone marrow may be compromised in these settings, and there are persisting concerns as to the possibility of stimulating clonal growth with hematopoietic growth factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Chemotherapy induced anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link\">",
"     \"Prognosis and treatment of primary myelofibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral and psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, information about the expected pattern and duration of fatigue should be offered to patients before they start treatment with chemotherapy, high-risk molecularly-targeted compounds, radiation therapy (RT), or biologic response modifiers. Multiple small randomized trials and a meta-analysis indicate that a variety of nonpharmacologic psychoeducation interventions are effective for improving cancer-related fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/17-23\">",
"     17-23",
"    </a>",
"    ], and its benefits have been shown to persist for at least two years after intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/24\">",
"     24",
"    </a>",
"    ]. However, whether all patients require formal cognitive behavioral therapy (CBT) by a psychologist or psychiatrist is unclear.",
"   </p>",
"   <p>",
"    To the extent that fatigue has a physiologic basis, cognitive-behavioral interventions may not be effective in all patients. In a randomized study that included 115 patients receiving radiation therapy for advanced cancer, a structured multidisciplinary program that included cognitive, emotional, physical, social, and spiritual interventions did not prevent the development of fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/25\">",
"     25",
"    </a>",
"    ], even though it was associated with an improvement in quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Type of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structured support groups are helpful for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/27-30\">",
"     27-30",
"    </a>",
"    ], although others may benefit from individual counseling for stress management, depression, and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/20,31-33\">",
"     20,31-33",
"    </a>",
"    ], stress",
"    <span class=\"nowrap\">",
"     management/relaxation",
"    </span>",
"    training [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/34-37\">",
"     34-37",
"    </a>",
"    ], or comprehensive programs that enhance coping skills through formal cognitive behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a variety of cognitive-behavioral and psychosocial interventions can be beneficial, discovering which patients benefit from what type of psychosocial intervention is an unresolved issue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/42\">",
"     42",
"    </a>",
"    ]. There are no randomized trials comparing different approaches, and as noted above, it is not clear that all patients require referral to a psychologist for formal CBT. The challenge to the practitioner is to match the characteristics of individual patients with the most helpful and cost-effective interventions.",
"   </p>",
"   <p>",
"    At the very least, all patients should be counseled as to general (",
"    <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"     table 2",
"    </a>",
"    ) and specific strategies (",
"    <a class=\"graphic graphic_table graphicRef53415 \" href=\"UTD.htm?6/16/6413\">",
"     table 3",
"    </a>",
"    ) to cope with fatigue and minimize energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/43\">",
"     43",
"    </a>",
"    ]. An example of a simple program of cognitive-behavioral intervention with specific adaptive strategies for management of symptoms such as fatigue is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef54322 \" href=\"UTD.htm?27/40/28299\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients should prioritize and pace activities in an attempt to conserve energy and delegate tasks to others, if feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/43\">",
"     43",
"    </a>",
"    ]. Nonessential activities should be postponed if moderate or severe fatigue is present. Daily self-monitoring in a treatment log or diary may help to identify peak energy periods and the effectiveness of specific interventions. Participation and incorporating family members in activities that are specifically designed to distract from the sense of fatigue (eg, card-playing, visiting) may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid fatigue, cancer patients often are advised to rest and downregulate their daily activities. However, because inactivity can induce muscular wasting, prolonged rest can lead to further loss of physical strength and endurance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/47\">",
"     47",
"    </a>",
"    ]. Although many fatigued patients have difficulty believing that exercise will improve their symptoms, physical exercise training programs can increase functional capacity, leading to reduced effort in performing usual activities and a decreased sense of fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research on the effects of exercise on cancer-related fatigue includes studies of patients receiving active treatment and those who have completed treatment. Experimental designs vary, sample sizes often are small, and many series are limited to women with breast cancer or men with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/52\">",
"     52",
"    </a>",
"    ]. The type of exercise is variable, with some studies evaluating walking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/4,50,53,54\">",
"     4,50,53,54",
"    </a>",
"    ], bicycling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], resistance training [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], or a combined approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/60-62\">",
"     60-62",
"    </a>",
"    ], and still others where the patient was allowed to choose the type of exercise he or she preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/48,63\">",
"     48,63",
"    </a>",
"    ]. The recommended exercise programs vary in length from six weeks to six months.",
"   </p>",
"   <p>",
"    Regardless of these limitations, all trials have demonstrated significant benefits (less fatigue and emotional distress, decreased sleep disturbance, improved functional capacity, and better QOL) for moderate exercise in patients with cancer. A Cochrane review of fatigue data from 56 randomized trials of patients with cancer-related fatigue concluded that exercise was significantly more effective than the control intervention regardless of whether it was delivered during or after adjuvant therapy, and that fatigue was significantly reduced by aerobic exercise but not resistance training or other alternative forms of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improved levels of aerobic physical activity may be facilitated by the use of printed materials, a step pedometer, or a combination of these approaches, rather than a simple recommendation to perform increased activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/65\">",
"     65",
"    </a>",
"    ]. Specific exercise programs should be preceded by a careful evaluation of comorbidities and exercise contraindications (such as extensive lytic bone metastases, extreme thrombocytopenia). The prescribed exercise program should be individualized and take into consideration the patient's age, gender, type of cancer and treatment, and the patient's physical fitness level. The initial intensity and duration of exercise should be low and slowly increased, as the patient's medical condition allows. Neutropenic patients must avoid environments where the risk of exposure to infectious agents is high (eg, public swimming pools).",
"   </p>",
"   <p>",
"    Consultation with other specialties and support services may be needed. For example, a patient whose physical activity is limited may need physical therapy and a rehabilitation evaluation to design an initial exercise program. Pool activities are an especially good form of physiotherapy.",
"   </p>",
"   <p>",
"    Each patient's treatment plan is unique and should be customized to fit his or her needs. Younger patients with limited or cured disease may be more motivated to engage in exercise programs than older patients or those with advanced disease or restrictive comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11096059\">",
"    <span class=\"h2\">",
"     Yoga",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials support a benefit for yoga in improving sleep quality and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The larger trial included 410 cancer survivors who reported moderate or severe sleep disruption within 2 to 24 months after completing adjuvant chemotherapy; the patients were randomly assigned to standard care monitoring with or without yoga [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/66\">",
"     66",
"    </a>",
"    ]. The yoga intervention consisted of breathing exercises, 18 gentle Hatha and restorative yoga postures, and meditation, performed twice weekly. In a preliminary report, after four weeks, yoga participants demonstrated greater improvements in sleep quality, fatigue, and quality of life from pre to post-intervention compared to controls (reduction in fatigue 42 versus 12 percent in the yoga and control groups, respectively). In addition, the yoga group demonstrated a greater reduction in daytime sleepiness (29 versus 5 percent) and reduced use of sleep medications (in contrast to the control group, in which use of sleep aids increased).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sleep therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbance associated with fatigue is often difficult to treat and manage. It may be influenced by numerous factors including daytime naps, depression, anxiety, medication, sleep interruption because of nocturia or hot flashes, and evening food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beverage intake (",
"    <a class=\"graphic graphic_table graphicRef50224 \" href=\"UTD.htm?8/44/8908\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although sleep disturbance is common in patients with cancer, few studies have evaluated sleep interventions to manage fatigue; the results are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study of 25 women receiving adjuvant chemotherapy for breast cancer, stimulus control (ie, having a consistent time to lie down and get up, avoiding caffeine and stimulating activity in the evening) and sleep restriction (ie, avoiding long or late-afternoon naps, limiting time in bed to the normal hours of sleep only) significantly improved fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=see_link\">",
"       \"Benefits and risks of caffeine and caffeinated beverages\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Benefit from a multimodality sleep hygiene program was suggested in a controlled study of two different relaxation techniques for up to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/69\">",
"       69",
"      </a>",
"      ]. Compared to the control group, both intervention groups had significantly better sleep latency, sleep duration, and daytime functioning. Effect on quality of life was not reported.",
"     </li>",
"     <li>",
"      In contrast, benefit from a sleep intervention could not be shown in a trial in which 219 patients receiving adjuvant chemotherapy for stage I to III breast cancer were randomly assigned to an individualized sleep therapy plan (stimulus control, sleep restriction, relaxation therapy and sleep hygiene, which was reinforced and revised at regular intervals) or a control group (who received only information about nutrition) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/70\">",
"       70",
"      </a>",
"      ]. Although the behavioral therapy intervention significantly improved global sleep quality at early time points, this did not translate into a significant impact on either objective sleep or fatigue outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cognitive-behavioral therapy and stress reduction also may help insomnia and sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Other suggestions for improving sleep patterns include taking a warm bath or drinking a glass of warm milk prior to bedtime, avoiding caffeinated beverages following dinner, emptying the bladder just before going to bed, and scheduling naps earlier in the day (",
"    <a class=\"graphic graphic_table graphicRef50224 \" href=\"UTD.htm?8/44/8908\">",
"     table 5",
"    </a>",
"    ). Some patients require medications to help them sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit from acupuncture has been suggested in at least three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. In the largest of these trials, 302 patients with nonmetastatic breast cancer who had completed chemotherapy at least a month and up to five years previously, and who were experiencing at least moderate fatigue (score &ge;5 on a scale of 1 to 10), were randomly assigned to usual care with and without acupuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/77\">",
"     77",
"    </a>",
"    ]. The usual care group received a booklet with information about fatigue and its management, while the acupuncture group received both the booklet and a once weekly treatment by an acupuncturist (needling three pairs of acupoints) for six weeks. The primary outcome was general fatigue at six weeks, as measured by the multidimensional fatigue inventory (MFI). Acupuncture was of significant benefit, with an estimated difference in the week 6 general fatigue score (acupuncture minus control) of -3.11 (95% CI -3.97 to -2.25), given equal baseline scores. Acupuncture also significantly improved other fatigue aspects as measure by the MFI, including physical and mental fatigue, anxiety and depression, and quality of life.",
"   </p>",
"   <p>",
"    A major problem with interpreting these results is the lack of a sham acupuncture control group; at least in the setting of chronic pain, both acupuncture and sham acupuncture have been shown to have much greater efficacy than no treatment, suggesting a strong placebo effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link&amp;anchor=H24#H24\">",
"     \"Acupuncture\", section on 'Summary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An earlier feasibility trial by this same group, which also showed a beneficial effect of acupuncture for cancer-related fatigue, included a sham acupressure but not sham acupuncture control group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/76\">",
"     76",
"    </a>",
"    ]. On the other hand, benefit from acupuncture could not be confirmed in a preliminary report of a randomized trial comparing acupuncture versus sham acupuncture in 97 patients with chronic chemotherapy-related fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/78\">",
"     78",
"    </a>",
"    ]. In both groups, scores on the BFI fell by about one point, and there was no significant difference between groups.",
"   </p>",
"   <p>",
"    These data are insufficient to conclude that there is benefit from acupuncture. Further studies in larger cohorts with a sham acupuncture control group are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacologic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although empiric administration of psychostimulants in patients with cancer-related fatigue has been reported to improve symptoms in open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/79-85\">",
"     79-85",
"    </a>",
"    ], double-blinded trials are needed to prove benefit in view of the subjective nature of fatigue, and the demonstrated therapeutic effect from placebo in at least one double-blind trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74068150\">",
"    <span class=\"h3\">",
"     Psychostimulants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Methylphenidate and dexmethylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is a central nervous system stimulant that is structurally related to amphetamines, with a short half-life and a rapid onset of action. Both the pharmacologic properties and clinical efficacy as a central nervous system stimulant reside in the d-isomer, which is available clinically as a distinct drug (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"     dexmethylphenidate",
"    </a>",
"    , Focalin), and effective at approximately one-half the dose of methylphenidate.",
"   </p>",
"   <p>",
"    Improvement in symptoms of fatigue, sedation, and pain was shown with these drugs in an uncontrolled prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/79\">",
"     79",
"    </a>",
"    ]. However, data from randomized controlled trials are mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 112 patients with a fatigue score of at least 4 on a scale of 0 to 10 were randomly assigned to 5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or placebo, with patients able to repeat dosing as needed every two hours to a maximum of four tablets per day [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/86\">",
"       86",
"      </a>",
"      ]. Patient-reported fatigue intensity improved over baseline by day 8 in both the methylphenidate- and placebo-treated patients. Thereafter, patients were given the option of receiving open-label methylphenidate. In the open label phase, the lower fatigue intensity was maintained through day 36.",
"      <br/>",
"      <br/>",
"      Within the constraints of a very early end point, this study could not identify clinical benefits that were attributable to treatment with methylphenidate and suggested that the observed benefits might be in part because of daily contact with the study nurse as well as a possible placebo effect. This is consistent with observations from other randomized trials that cancer-related fatigue can benefit from active psychosocial intervention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cognitive-behavioral and psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"       dexmethylphenidate",
"      </a>",
"      was suggested in a randomized phase II trial in which 152 patients who received &ge;4 cycles of chemotherapy and had persistent fatigue and cognitive impairment at least two months after treatment were randomly assigned to dexmethylphenidate (5 mg twice daily or as needed up to 20 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/87\">",
"       87",
"      </a>",
"      ]. After eight weeks, the use of dexmethylphenidate was associated with a significant improvement in fatigue but not cognitive function.",
"     </li>",
"     <li>",
"      Benefit from long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      could not be shown in a randomized, placebo-controlled NCCTG trial involving 148 adult patients with a history of cancer-related fatigue for at least one month [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/88\">",
"       88",
"      </a>",
"      ]. Fatigue assessments were performed weekly using the BFI (",
"      <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"       table 6",
"      </a>",
"      ). Over the course of four weeks, long-acting methylphenidate (target dose 54 mg daily) did not improve cancer related fatigue and it caused significantly higher levels of nervousness and appetite loss. Post-hoc subset analysis suggested some benefit from methylphenidate in patients with more severe fatigue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more advanced cancer (stage III or IV disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Dextroamphetamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit could not be shown for dexamphetamine (10 mg twice daily) in a placebo-controlled trial involving 50 fatigued patients with advanced cancer who were receiving palliative care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/89\">",
"     89",
"    </a>",
"    ]. However, the short duration of treatment (eight days), poor performance status of the group as a whole (the majority ECOG 3, (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 7",
"    </a>",
"    )), and the wide array of other neurologically active medications being administered could all have contributed to the negative result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Modafinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    , a non-amphetamine \"wake-promoting agent\", is used for the treatment of narcolepsy. Limited experience in cancer patients suggests that modafinil is well tolerated and may be a useful treatment for cancer-related fatigue, particularly in patients with severe fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. The benefits of modafinil in the treatment of cancer-related fatigue can be illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two separate pilot studies, a total of 47 patients with a current diagnosis of cancer complicated by fatigue were given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      (100 mg daily for seven days followed by 200 mg daily for seven days) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/90,93\">",
"       90,93",
"      </a>",
"      ]. There was a rapid and statistically significant reduction in fatigue in the majority of patients, which were accompanied by improvements in daytime sleepiness,",
"      <span class=\"nowrap\">",
"       depression/anxiety,",
"      </span>",
"      and performance status.",
"     </li>",
"     <li>",
"      Benefit was addressed in a randomized trial in which 867 patients self-reporting fatigue during chemotherapy (a value of &gt;1 on a BFI scale, item 3 of 0 to 10, (",
"      <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"       table 6",
"      </a>",
"      )) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      (200 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/94\">",
"       94",
"      </a>",
"      ]. In an analysis of 631 patients with evaluable data, modafinil significantly reduced fatigue only for the subgroup of patients with high baseline fatigue (BFI item 3 score &ge;7, (",
"      <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"       table 6",
"      </a>",
"      )) while there were no significant differences in patients with mild to moderate fatigue at baseline. Modafinil did not improve depression, reinforcing the view that depression and cancer-related fatigue are not linked.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    were not addressed in the above-mentioned meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74068182\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;These results suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    could be considered in patients with severe cancer-related fatigue (BFI item 3 score &ge;7). Benefit is less certain in patients with mild to moderate fatigue. Starting doses of modafinil are usually 100 to 200 mg in the morning and again at noon. The maximum daily dose is 400 mg. We suggest starting methylphenidate at 5 mg in the morning, and 5 mg at noon, titrating as necessary. The maximal dose with the potential for benefit in cancer related fatigue is 40 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10231194\">",
"    <span class=\"h3\">",
"     Testosterone for hypogonadal men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism affects two-thirds of men with advanced cancer. Previous studies have shown that low testosterone levels in men with cancer are associated with fatigue, anorexia, depression, and insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testosterone replacement improves quality of life and diminishes fatigue in patients with noncancer conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H13#H13\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of testosterone replacement for treatment of fatigue in hypogonadal men with advanced cancer was addressed in a small trial in which 14 patients treated with placebo and 12 patients treated with testosterone (weight-based intramuscular testosterone administered every 14 days to achieve a bioavailable testosterone level 70 to",
"    <span class=\"nowrap\">",
"     270ng/dL)",
"    </span>",
"    were evaluable for the primary outcome at day 29 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/96\">",
"     96",
"    </a>",
"    ]. In a preliminary report presented at the 2012 meeting of the American Society of Clinical Oncology, no statistically significant difference was found for FACIT-F total scores between arms, but there was a trend for testosterone to improve fatigue scores (mean [SD] was -5.5 &plusmn; 19 for placebo and 3.9 &plusmn; 14 for testosterone, p = 0.09). Adverse events were similar between groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three placebo-controlled, randomized trials in patients undergoing cancer treatment have failed to demonstrate any improvement in fatigue in patients randomly assigned to receive an antidepressant (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ), despite improvement in depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, antidepressants may be helpful when a patient has both fatigue and depression. For patients who also have insomnia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    are good choices. Case reports suggest efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    in patients with chronic fatigue syndrome, but no data are available in patients with cancer-related fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are beneficial for some patients with cancer-related fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]; however, side effects limit their long-term use. Steroids may be most helpful for patients with cancer-related fatigue who are in the terminal phase of advanced cancer. Dose management is important, as this class of drugs may induce insomnia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Donepezil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pilot studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    , a selective acetylcholinesterase inhibitor, suggested that this approach might be useful in patients with cancer-related fatigue. However, a randomized trial did not show any benefit compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Multivitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multivitamins have been assessed in a small randomized trial, in an effort to ameliorate the fatigue in women receiving radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/103\">",
"     103",
"    </a>",
"    ]. No benefit could be ascribed to the use of multivitamins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24908748\">",
"    <span class=\"h3\">",
"     Ginseng and guarana",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit for American Ginseng (2000 mg daily of a pure ground product) was suggested in a double-blind, placebo-controlled randomized trial conducted by the North Central Cancer Treatment Group (NCCTG) in 364 patients with cancer undergoing or having completed curative intent therapy and who had a fatigue score of four or more (on a scale of 1 to 10) for at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/104\">",
"     104",
"    </a>",
"    ]. In a preliminary report presented at the 2012 meeting of the American Society of Clinical Oncology (ASCO), patients assigned to Ginseng had significantly better scores on the general and physical subscales of the Multidimensional Fatigue Symptom Inventory at eight but not four weeks without side effects, but there was no impact on mental, emotional, or vigor dimensions of fatigue.",
"   </p>",
"   <p>",
"    While these data seem promising, additional studies are needed to confirm these findings before ginseng can be recommended as a treatment for CRF, particularly in view of the potential for drug interactions with Ginseng. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H41#H41\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Interactions of CAM with conventional treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guarana is a stimulant derived from an extract of seeds from a plant in the Amazon (Paullinia cupana). In a double-blind, placebo-controlled study of breast cancer patients receiving chemotherapy, oral guarana at a dose of 100 mg daily significantly improved fatigue scores at the end of 21 days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/105\">",
"     105",
"    </a>",
"    ]. Further studies are needed to confirm these results, to evaluate their generalizability to chronic cancer-related fatigue and to other types of cancer, and to evaluate long-term side effects and drug-drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25258574\">",
"    <span class=\"h2\">",
"     Combined approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of a combined approach to intervention were studied in a trial in which 273 survivors with moderate to severe cancer-related fatigue (&ge;4 on the BFI (",
"    <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"     table 6",
"    </a>",
"    )) who had completed primary cancer treatment within the past 24 months were randomly assigned to a 12-week individually tailored CRF program versus routine care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/106\">",
"     106",
"    </a>",
"    ]. The intervention, which was based upon",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    for management of CRF, consisted of internet-based educational information covering six strategic areas of energy conservation, physical activity, nutrition, sleep hygiene, pain control, and distress management, as well as a general introduction to CRF that allowed individual patients to evaluate their CRF status. Patients were assessed at baseline and at 12 weeks with the BFI (",
"    <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"     table 6",
"    </a>",
"    ) and Fatigue Severity Scale (FSS, ranked on a seven-point scale) for the primary outcome, and the Hospital Anxiety and Depression Scale (HADS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) for secondary outcomes.",
"   </p>",
"   <p>",
"    Patients who received the intervention had a significantly greater decrease in BFI global score (-0.66, 95% CI -1.04 to -0.27) and FSS total score (-0.49, 95% CI -0.78 to -0.21) from baseline, although the clinical meaningfulness of these small differences is unclear. The intervention group also experienced a significantly greater decreases in HADS score, and global QOL, but the differences were also small and of unclear clinical meaningfulness.",
"   </p>",
"   <p>",
"    Further study of educational interventions in a variety of cancer patients (those under current treatment with differing interventions, those without evidence of malignancy and on no treatment, etc) and in different geographical and cultural environments are necessary to determine the impact of any educational intervention on CRF in these different settings. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     A CANCER-RELATED FATIGUE CLINIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cancer-Related Fatigue Clinic at the University of Texas M. D. Anderson Cancer Center was developed in 1998 to improve quality of life for patients with cancer by addressing and alleviating cancer-related fatigue.",
"   </p>",
"   <p>",
"    Through 2005, 260 patients have been evaluated in our clinic, and the most recent update of our experience addresses treatment success and the number of visits required for symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/107\">",
"     107",
"    </a>",
"    ]. For all patients, baseline and follow-up fatigue categories were assessed according to scores on the Brief Fatigue Inventory (BFI, (",
"    <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/108\">",
"     108",
"    </a>",
"    ]) and categorized as severe or nonsevere (moderate or mild). Treatment success was defined as a reduction in baseline fatigue to the lesser fatigue category or subcategory according to the BFI, the primary outcome measure. For patients with treatment success, the follow-up visit number at which fatigue reduction was achieved was recorded (the secondary outcome measure).",
"   </p>",
"   <p>",
"    The 260 patients with baseline fatigue data had a mean age of 56 years (range 24 to 86 years). The most common diagnosis was breast cancer (33 percent, n=87). Thirty percent were receiving cancer treatment at the time of their initial evaluation for fatigue. Nearly one-half of patients reported severe fatigue at baseline (47 percent, n=123); of those with nonsevere fatigue, 80 percent (n=110) had moderate and 20 percent (n=27) had mild fatigue. Patients with severe fatigue reported significantly worse symptom status than patients with nonsevere fatigue, including pain, sleep disturbance, depression, poor functional status, and anxiety.",
"   </p>",
"   <p>",
"    The treatment interventions most frequently discussed and prescribed were energy conservation, sleep hygiene, and exercise plans. An antidepressant, analgesic, stimulant or anxiolytic medication was recommended to 27, 25, 22, and 17 percent, respectively.",
"   </p>",
"   <p>",
"    With specific treatment aimed at the cause of the fatigue, 59 percent achieved targeted fatigue reductions, including 47 of 69 patients whose severe fatigue decreased to nonsevere fatigue at the first follow-up visit (67 percent success rate) and 49 percent (28 of 57) of moderately-fatigued patients who had a reduction to mild fatigue. Of the 74 successfully treated patients, 62 percent (n=46) reported success by the first follow-up visit and 22 percent (n=16) by the second visit. Thus, the CRF Clinic improved fatigue for a majority of returning patients within two follow-up visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       \"Patient information: When your cancer treatment makes you tired (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-related fatigue is a common, distressing, and potentially treatable condition. The most important factors contributing to cancer-related fatigue are treatment with cytotoxic chemotherapy, biologic response modifiers, molecularly targeted therapy (particularly the small molecular tyrosine kinase inhibitors and the therapeutic monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) or radiation therapy, anemia, pain (and its treatment), emotional distress, sleep disturbance, poor nutrition, and other comorbidities. Although most common during active cancer therapy, cancer-related fatigue may affect patients long after cancer treatment has been completed. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Screening and assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be screened for fatigue at the initial visit, at the time that advanced disease is diagnosed, and at all chemotherapy visits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. A simple visual analog scale rating fatigue (VAS, \"How would you rate your fatigue on a scale of 0 to 10\", with 0 representing no fatigue and 10 the worst imaginable fatigue) is a reasonable approach to screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mild fatigue (VAS score 1 to 3) that does not interfere with activities of daily living (ADLs) can be reassured and counseled as to coping strategies that conserve energy (",
"    <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53415 \" href=\"UTD.htm?6/16/6413\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fatigue that is moderate to severe (four or higher on the VAS) or interferes with ADLs requires a comprehensive fatigue evaluation with a complete history, review of systems, physical examination, diagnostic studies, and objective assessment of associated symptoms. Factors that are often causally related to cancer-related fatigue that should be specifically assessed include anemia, pain (and its treatment), emotional",
"    <span class=\"nowrap\">",
"     distress/mood",
"    </span>",
"    disturbance, difficulties with sleep, poor nutrition and electrolyte disturbances (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"UTD.htm?4/38/4715\">",
"     table 8",
"    </a>",
"    ), activity level, and the presence of comorbidities such as cardiac or pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Need for further evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If any of the factors known to be associated with cancer-related fatigue are identified (eg, abnormal serum electrolytes or hypothyroidism), they should be treated as the initial approach to fatigue. Optimizing management of physical symptoms such as pain, nausea, and dyspnea can help to alleviate fatigue. For patients with fatigue and cancer-related pain, opioid analgesics should be titrated or the",
"      <span class=\"nowrap\">",
"       schedule/agent",
"      </span>",
"      modified so as to alleviate pain without significantly altering mentation. If needed, a trial of psychostimulants may help to reverse opioid-related sedation. (See",
"      <a class=\"local\" href=\"#H606308092\">",
"       'Control of physical symptoms'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia is the most common reversible cause of fatigue in patients with cancer and may be due either to cancer treatment or the underlying disease. The underlying causes of anemia should be identified and treated if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a potentially reversible cause of the anemia cannot be identified, treatment options include erythropoiesis stimulating agents (ESAs) or red blood cell (RBC) transfusion. A table illustrating the risks and benefits of ESAs versus transfusion is provided (",
"      <a class=\"graphic graphic_table graphicRef78476 \" href=\"UTD.htm?31/32/32267\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cancer patients who are being considered for treatment with ESAs should meet all of the following criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?26/29/27098/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H28#H28\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Summary: patient selection for ESAs'",
"      </a>",
"      .):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anemia should be due to chemotherapy treatment for a nonhematologic malignancy.",
"     </li>",
"     <li>",
"      Other treatable causes of anemia (eg, blood loss, hemolysis, nutritional deficiency (eg, iron, B12, folate)) should be excluded or treated if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An initial hemoglobin level of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or less should be present, although patients with a hemoglobin level between 10 and 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      who are highly symptomatic can also be considered for ESA therapy on an individual basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with fatigue who meet all of these criteria, we suggest treatment with an ESA rather than RBC transfusions alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment with RBC transfusions is an appropriate alternative for patients whose clinical condition indicates the need for immediate correction of the hemoglobin level and for those in whom reducing the frequency of transfusion is not an important consideration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ESAs'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      There is controversy as to whether use of ESAs should be avoided in anemic patients who are receiving myelosuppressive chemotherapy with the intent of cure. This topic is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H28#H28\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Summary: patient selection for ESAs'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Even if indicated, ESAs should be used cautiously in patients with a high risk for thromboembolism, especially in the setting of malignancies that are associated with an elevated risk for thromboembolic complications (eg, advanced pancreatic cancer).",
"     </li>",
"     <li>",
"      For patients with nonhematologic malignancies who have fatigue related to anemia but are not receiving cytotoxic chemotherapy, we recommend transfusion rather than an ESA (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H18#H18\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Use in patients not receiving chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have symptomatic anemia related to a hematologic malignancy or premalignant condition such as myelodysplastic syndrome, the issues surrounding the use of ESAs are more complex, and specific recommendations depend on the clinical situation. Management of symptomatic anemia in these settings is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Chemotherapy induced anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link\">",
"       \"Prognosis and treatment of primary myelofibrosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"       \"Hematopoietic support after hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Nonpharmacologic management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with cancer-related fatigue, we suggest some form of cognitive-behavioral intervention (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). To the extent that fatigue has a physiologic basis, cognitive-behavioral interventions may not be effective in all patients. &nbsp;",
"      <br/>",
"      <br/>",
"      A variety of approaches may be used. &nbsp;At the very least, all patients should be counseled as to general (",
"      <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"       table 2",
"      </a>",
"      ) and specific strategies (",
"      <a class=\"graphic graphic_table graphicRef53415 \" href=\"UTD.htm?6/16/6413\">",
"       table 3",
"      </a>",
"      ) to cope with fatigue and minimize energy expenditures. Structured support groups are helpful for some patients, while others may benefit from individual counseling for stress management, depression, and anxiety, stress",
"      <span class=\"nowrap\">",
"       management/relaxation",
"      </span>",
"      training, or comprehensive programs that enhance coping skills through formal cognitive behavioral therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cognitive-behavioral and psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frequent napping during the day can interfere with a restful, \"restorative\" night's rest. It is important to establish regular bed and waking times, and to perform restful activities before going to bed (",
"      <a class=\"graphic graphic_table graphicRef50224 \" href=\"UTD.htm?8/44/8908\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sleep therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unless contraindicated (eg, by the presence of extensive lytic bone metastases or extreme thrombocytopenia),",
"      <strong>",
"      </strong>",
"      we recommend an individualized program of moderate aerobic exercise",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Yoga may also improve sleep quality and fatigue. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits of acupuncture for cancer-related fatigue remain unclear. However, given the overall safety of this approach, interested patients could be referred for a trial of acupuncture if symptoms of moderate to severe fatigue persist despite other forms of therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acupuncture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Psychostimulants and antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe fatigue (BFI, question #3 &gt;7) in whom nonpharmacologic methods do not resolve fatigue, and anemia is being treated or noncontributory, we suggest a trial of a psychostimulant (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"       dexmethylphenidate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacologic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a therapeutic trial of an antidepressant in patients with fatigue accompanied by a significant mood disorder (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6679170\">",
"    <span class=\"h3\">",
"     Other pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are in the terminal phase of their illness who have a high symptom burden that includes fatigue may be considered for a trial of glucocorticoid therapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Steroids'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10689694\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providing information to better educate patients and families regarding CRF and its management is highly encouraged.&nbsp;A web-based combined educational intervention for CRF has been shown to be beneficial, but the&nbsp;positive changes were relatively small and the clinical significance of the findings is unknown. (See",
"    <a class=\"local\" href=\"#H25258574\">",
"     'Combined approach'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/2\">",
"      Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/3\">",
"      Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996; 4:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/4\">",
"      Mock V, Dow KH, Meares CJ, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997; 24:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/5\">",
"      Bloom JR, Fobair P, Gritz E, et al. Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer. J Clin Oncol 1993; 11:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/6\">",
"      Dagnelie PC, Pijls-Johannesma MC, Lambin P, et al. Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 2007; 18:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/7\">",
"      Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007; 34:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/8\">",
"      Spelten ER, Verbeek JH, Uitterhoeve AL, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer 2003; 39:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/9\">",
"      Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/10\">",
"      Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008; 26:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/11\">",
"      de Raaf PJ, de Klerk C, Timman R, et al. Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 2013; 31:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/12\">",
"      Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev 2012; 2:CD009007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/13\">",
"      Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100:1155.",
"     </a>",
"    </li>",
"    <li>",
"     Revicki D, Stull D, Viswanathan H, et al. The effect of darbepoietin alfa on patient-reported fatigue in cancer patients: Results from three phase III clinical trials (abstract). J Clin Oncol 2008; 26:530s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/15\">",
"      Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     Press release available at www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf (Accessed on July 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/17\">",
"      Barsevick AM, Dudley W, Beck S, et al. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 2004; 100:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/18\">",
"      Ream E, Richardson A, Alexander-Dann C. Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 2006; 31:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/19\">",
"      Armes J, Chalder T, Addington-Hall J, et al. A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue. Cancer 2007; 110:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/20\">",
"      Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2005; 23:6027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/21\">",
"      Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/22\">",
"      Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009; :CD006953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/23\">",
"      Kwekkeboom KL, Abbott-Anderson K, Cherwin C, et al. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. J Pain Symptom Manage 2012; 44:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/24\">",
"      Gielissen MF, Verhagen CA, Bleijenberg G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer 2007; 97:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/25\">",
"      Brown P, Clark MM, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol 2006; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/26\">",
"      Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/27\">",
"      Weis J. Support groups for cancer patients. Support Care Cancer 2003; 11:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/28\">",
"      Helgeson VS, Cohen S, Schulz R, Yasko J. Group support interventions for women with breast cancer: who benefits from what? Health Psychol 2000; 19:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/29\">",
"      Forester B, Kornfeld DS, Fleiss JL, Thompson S. Group psychotherapy during radiotherapy: effects on emotional and physical distress. Am J Psychiatry 1993; 150:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/30\">",
"      Boesen EH, Ross L, Frederiksen K, et al. Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005; 23:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/31\">",
"      Forester B, Kornfeld DS, Fleiss JL. Psychotherapy during radiotherapy: effects on emotional and physical distress. Am J Psychiatry 1985; 142:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/32\">",
"      Given B, Given CW, McCorkle R, et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 2002; 29:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/33\">",
"      Trijsburg RW, van Knippenberg FC, Rijpma SE. Effects of psychological treatment on cancer patients: a critical review. Psychosom Med 1992; 54:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/34\">",
"      Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 2002; 20:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/35\">",
"      Decker TW, Cline-Elsen J, Gallagher M. Relaxation therapy as an adjunct in radiation oncology. J Clin Psychol 1992; 48:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/36\">",
"      Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004; 29:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/37\">",
"      Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology 2001; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/38\">",
"      Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs 2000; 23:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/39\">",
"      Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. J Clin Oncol 2004; 22:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/40\">",
"      Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 2006; 24:4882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/41\">",
"      Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. J Clin Oncol 2005; 23:6009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/42\">",
"      Clark MM, Bostwick JM, Rummans TA. Group and individual treatment strategies for distress in cancer patients. Mayo Clin Proc 2003; 78:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/43\">",
"      Barsevick AM, Whitmer K, Sweeney C, Nail LM. A pilot study examining energy conservation for cancer treatment-related fatigue. Cancer Nurs 2002; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/44\">",
"      Graydon JE, Bubela N, Irvine D, Vincent L. Fatigue-reducing strategies used by patients receiving treatment for cancer. Cancer Nurs 1995; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/45\">",
"      Richardson A, Ream EK. Self-care behaviours initiated by chemotherapy patients in response to fatigue. Int J Nurs Stud 1997; 34:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/46\">",
"      Schneider SM, Prince-Paul M, Allen MJ, et al. Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum 2004; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/47\">",
"      Luc&iacute;a A, Earnest C, P&eacute;rez M. Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol 2003; 4:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/48\">",
"      Segal R, Evans W, Johnson D, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 2001; 19:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/49\">",
"      Dimeo F, Fetscher S, Lange W, et al. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 1997; 90:3390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/50\">",
"      Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 2004; 101:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/51\">",
"      Thorsen L, Skovlund E, Str&oslash;mme SB, et al. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 2005; 23:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/52\">",
"      Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage 2012; 43:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/53\">",
"      Griffith K, Wenzel J, Shang J, et al. Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors. Cancer 2009; 115:4874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/54\">",
"      Dimeo F, Schwartz S, Fietz T, et al. Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer 2003; 11:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/55\">",
"      Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999; 85:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/56\">",
"      Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003; 21:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/57\">",
"      Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27:4605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/58\">",
"      Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/59\">",
"      Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/60\">",
"      Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2008; 108:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/61\">",
"      Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ 2009; 339:b3410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/62\">",
"      Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/63\">",
"      Schwartz AL, Mori M, Gao R, et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc 2001; 33:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/64\">",
"      Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012; 11:CD006145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/65\">",
"      Vallance JK, Courneya KS, Plotnikoff RC, et al. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol 2007; 25:2352.",
"     </a>",
"    </li>",
"    <li>",
"     Mustian KM, Palesh O, Sprod L, et al. Effect of YOCAS yoga on sleep, fatigue, and quality of life: a URCC CCOP randomized controlled clinical trial among 410 cancer survivors (abstract 9013). J Clin Oncol 2010; 28:639s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/67\">",
"      Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer 2012; 118:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/68\">",
"      Berger AM, VonEssen S, Khun BR, et al. Feasibilty of a sleep intervention during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 2002; 29:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/69\">",
"      Simeit R, Deck R, Conta-Marx B. Sleep management training for cancer patients with insomnia. Support Care Cancer 2004; 12:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/70\">",
"      Berger AM, Kuhn BR, Farr LA, et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 2009; 27:6033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/71\">",
"      Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003; 71:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/72\">",
"      Shapiro SL, Bootzin RR, Figueredo AJ, et al. The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. J Psychosom Res 2003; 54:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/73\">",
"      Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 2005; 23:6083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/74\">",
"      Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008; 26:4651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/75\">",
"      Vickers AJ, Straus DJ, Fearon B, Cassileth BR. Acupuncture for postchemotherapy fatigue: a phase II study. J Clin Oncol 2004; 22:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/76\">",
"      Molassiotis A, Sylt P, Diggins H. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: a randomised controlled trial. Complement Ther Med 2007; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/77\">",
"      Molassiotis A, Bardy J, Finnegan-John J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol 2012; 30:4470.",
"     </a>",
"    </li>",
"    <li>",
"     Deng GE, et al. Acupuncture for chemotherapy-inducced fatigue (abstract 9029). J Clin Oncol 2011; 29:557s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=84158 (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/79\">",
"      Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21:4439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/80\">",
"      Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/81\">",
"      Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/82\">",
"      Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29:E85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/83\">",
"      Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/84\">",
"      Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/85\">",
"      Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/86\">",
"      Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/87\">",
"      Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009; 38:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/88\">",
"      Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010; 28:3673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/89\">",
"      Auret KA, Schug SA, Bremner AP, Bulsara M. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage 2009; 37:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/90\">",
"      Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 2009; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     Kohli S, Fisher SG, Tra Y, et al. The cognitive effects of modafinil in breast cancer survivors: A randomized clinical trial (abstract). J Clin Oncol 2007; 25:494s.",
"    </li>",
"    <li>",
"     Morrow GR, Jean-Pierre P, Roscoe JA, et al. A phase III randomized, pacebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study (abstract). J Clin Oncol 2008; 504:s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/93\">",
"      Blackhall L, Petroni G, Shu J, et al. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 2009; 12:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/94\">",
"      Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010; 116:3513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/95\">",
"      Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39:1016.",
"     </a>",
"    </li>",
"    <li>",
"     Pulivarthi K, Dev R, Garcia J, et al. Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial. J Clin Oncol 30, 2012 (suppl; abstr e19643) Abstract available online at   . file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=101245 (Accessed on August 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/97\">",
"      Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/98\">",
"      Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 2007; 8:603.",
"     </a>",
"    </li>",
"    <li>",
"     Palesh O, Mustian KM, Roscoe JA, et al. Effect of paroxetime on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy (abstract). J Clin Oncol 2008; 26:502s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/100\">",
"      Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, et al. Dexamethasone (DM) for cancer-related fatigue: a double-blinded, randomized, placebo-controlled tiral. J Clin Oncol 30, 2012 (suppl; abstract 9002). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99080 (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/102\">",
"      Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007; 25:3475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/103\">",
"      de Souza F&ecirc;de AB, Bensi CG, Trufelli DC, et al. Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol 2007; 30:432.",
"     </a>",
"    </li>",
"    <li>",
"     Barton DL, Liu H, Dakhil SR,  et al. Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2. J Clin Oncol 30, 2012 (suppl; abstract 9001). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=94721 (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/105\">",
"      de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med 2011; 17:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/106\">",
"      Yun YH, Lee KS, Kim YW, et al. Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial. J Clin Oncol 2012; 30:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/107\">",
"      Escalante CP, Kallen MA, Valdres RU, et al. Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. J Pain Symptom Manage 2010; 39:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/29/27098/abstract/108\">",
"      Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2813 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27098=[""].join("\n");
var outline_f26_29_27098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606308092\">",
"      Control of physical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Management of anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10231168\">",
"      - Transfusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - ESAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cognitive-behavioral and psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Type of intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11096059\">",
"      Yoga",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sleep therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H74068150\">",
"      - Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methylphenidate and dexmethylphenidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dextroamphetamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Modafinil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H74068182\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10231194\">",
"      - Testosterone for hypogonadal men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Steroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Donepezil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Multivitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24908748\">",
"      - Ginseng and guarana",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25258574\">",
"      Combined approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      A CANCER-RELATED FATIGUE CLINIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Screening and assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Psychostimulants and antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6679170\">",
"      - Other pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10689694\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2813|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/32/32267\" title=\"table 1\">",
"      Risk ben ESA RBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17149\" title=\"table 2\">",
"      Energy conservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/16/6413\" title=\"table 3\">",
"      Energy preservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/40/28299\" title=\"table 4\">",
"      Cognit behav intervent fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/44/8908\" title=\"table 5\">",
"      Good sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/29/9692\" title=\"table 6\">",
"      Brief fatigue inventory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 7\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4715\" title=\"table 8\">",
"      Cancer related fatigue initial workup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=related_link\">",
"      Various rehabilitation issues in patients treated for cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_29_27099="Saline load test";
var content_f26_29_27099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Saline load test",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Test performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Place a No. 16 French nasogastric sump tube into the stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Position the tip 65 cm from the nares",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Empty the stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Place patient right side down",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Infuse 750 mL of isotonic (0.9%) saline into the tube over 3 to 5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        After 30 min, aspirate and measure gastric residual volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Interpretation of gastric residual volume:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;400 mL:",
"       </td>",
"       <td>",
"        Definite gastric outlet obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        300 to 400 mL:",
"       </td>",
"       <td>",
"        Probable gastric outlet obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 to 300 mL:",
"       </td>",
"       <td>",
"        Indeterminate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200 mL:",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Graham DY. In: Gastrointestinal Disease, 5th ed, Sleisenger M, Fordtran J (Eds), WB Saunders, Philadelphia 1993. p.698.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27099=[""].join("\n");
var outline_f26_29_27099=null;
var title_f26_29_27100="History and limp etiology in children";
var content_f26_29_27100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Historical features associated with specific causes of limp in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Historical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Causes of limp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever, weight loss, anorexia",
"       </td>",
"       <td>",
"        Malignancy, osteomyelitis, septic arthritis, chronic rheumatoid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of trauma (trivial to major)",
"       </td>",
"       <td>",
"        Fracture, contusion, slipped capital femoral epiphysis, osteochondritis dessicans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activity increases pain",
"       </td>",
"       <td>",
"        Stress fracture, benign hypermobility syndrome, overuse syndromes, compartment syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activity decreases pain",
"       </td>",
"       <td>",
"        Juvenile idiopathic arthritis, complex regional pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent viral illness or antibiotic use",
"       </td>",
"       <td>",
"        Immune complex mediated diseases such as transient synovitis, Henoch-Sch&ouml;nlein purpura, serum sickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclic pattern, noctural",
"       </td>",
"       <td>",
"        Osteoid osteoma, malignant bone tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morning stiffness",
"       </td>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New or increased sport activity",
"       </td>",
"       <td>",
"        Stress fractures, overuse syndromes, Osgood-Schlatter disease, chrondomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramuscular injection vaccinations",
"       </td>",
"       <td>",
"        Sterile abscess, muscle inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New or poorly fitting shoes",
"       </td>",
"       <td>",
"        Pressure necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychosocial problems",
"       </td>",
"       <td>",
"        Child abuse, complex regional pain syndrome (eg, reflex sympathetic dystrophy), conversion reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of connective tissue disorders",
"       </td>",
"       <td>",
"        Systemic lupus erythematosus, sarcoid, juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migratory arthralgia",
"       </td>",
"       <td>",
"        Acute rheumatic fever, gonococcal arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Back pain",
"       </td>",
"       <td>",
"        Discitis, meningitis, vertebral osteomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrinopathies",
"       </td>",
"       <td>",
"        Slipped capital femoral epiphysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Phillips WA. Orthop Clin North Am 1987; 18:489; and Kost S. Limp. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henertig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.415.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27100=[""].join("\n");
var outline_f26_29_27100=null;
var title_f26_29_27101="Intestinal pathogen exposure I";
var content_f26_29_27101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75543%7EID%2F55625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75543%7EID%2F55625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Exposures associated with specific intestinal pathogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiologic clue(s) to",
"diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        Beef, pork, poultry, eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium perfringens",
"       </td>",
"       <td>",
"        Beef, pork, poultry, home-canned foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacillus cereus",
"       </td>",
"       <td>",
"        Beef, pork, fried rice (Chinese), vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterhemorrhagic E. coli",
"       </td>",
"       <td>",
"        Beef, pork, fast food restaurants (undercooked",
"hamburger), apple cider, leaf lettuce, milk, cheese, extremes of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroinvasive E. coli",
"       </td>",
"       <td>",
"        Milk, cheese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterotoxigenic E. coli",
"       </td>",
"       <td>",
"        Travelers to developing world",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmonella",
"       </td>",
"       <td>",
"        Beef, pork, poultry, eggs, (eg, Caesar salad), raw",
"milk, ice cream, vegetables (eg, alfalfa sprouts), unpasteurized orange",
"juice, pet ducklings, lizards, rattlesnake meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Campylobacter",
"       </td>",
"       <td>",
"        Poultry (undercooked at barbecues), raw milk and cheeses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shigella",
"       </td>",
"       <td>",
"        Daycare centers, vegetables (eg, green onions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yersinia",
"       </td>",
"       <td>",
"        Pork (not common), beef, milk, cheeses, hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio cholerae",
"       </td>",
"       <td>",
"        Shellfish from the Gulf of Mexico, inadequately cooked",
"seafood from South America, coconut milk from Thailand, airline",
"outbreaks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio parahaemolyticus",
"       </td>",
"       <td>",
"        Ingestion of raw seafood, particularly in East Asia,",
"shellfish, cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium difficile",
"       </td>",
"       <td>",
"        Hospitalization, inpatient or outpatient antibiotic(s)",
"or chemotherapy within the last several weeks, daycare centers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Listeria",
"       </td>",
"       <td>",
"        Beef, pork, poultry, milk cheese, coleslaw, hot dogs,",
"potato salad, pregnancy, neonates, immunocompromised patients",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Exposures associated with specific intestinal pathogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiologic clue(s) to",
"diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rotavirus",
"       </td>",
"       <td>",
"        Daycare centers, nurseries, Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noroviruses",
"       </td>",
"       <td>",
"        Schools, nursing homes, cruise ships, camps, military",
"barracks, vegetables, waterborne, foodborne, and shellfish-associated",
"outbreaks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis A",
"       </td>",
"       <td>",
"        Overcrowding, lack of clean water, patients and staff",
"of institutions, day care centers, men who have sex with men, IV drug",
"users, travelers, military barracks, shellfish (clams, oysters, mussels)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"       <td>",
"        Infantile diarrhea, ?AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        HIV-infected homosexual men with AIDS, organ",
"transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardia lamblia",
"       </td>",
"       <td>",
"        Daycare centers, swimming pools, travel (eg, St.",
"Petersburg, mountainous areas with ingestion of stream water), fruit",
"salad",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Entamoeba histolytica",
"       </td>",
"       <td>",
"        Travelers to endemic areas (eg, Mexico), for more than",
"one month, men who have sex with men, institutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptosporidium",
"       </td>",
"       <td>",
"        Daycare centers, swimming pools, AIDS, farm animal",
"exposure, city water supply contamination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclospora",
"       </td>",
"       <td>",
"        Raspberries (from Guatemala)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isospora",
"       </td>",
"       <td>",
"        Haiti, HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microsporidium",
"       </td>",
"       <td>",
"        AIDS (? travelers, ? fresh water)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27101=[""].join("\n");
var outline_f26_29_27101=null;
var title_f26_29_27102="Causes death children";
var content_f26_29_27102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    10 leading causes of death, United States (&lt;1 to 24 years) 2009, all races, both sexes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Rank",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Age groups, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;1",
"       </td>",
"       <td class=\"subtitle2\">",
"        1-4",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-9",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-14",
"       </td>",
"       <td class=\"subtitle2\">",
"        15-19",
"       </td>",
"       <td class=\"subtitle2\">",
"        20-24&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         5319",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #0000ff;\">",
"          Unintentional injury",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #0000ff;\">",
"          1466",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"blue\">",
"          Unintentional injury",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"blue\">",
"          773",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"blue\">",
"          Unintentional injury",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"blue\">",
"          916",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"blue\">",
"          Unintentional injury",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"blue\">",
"          4807",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #0000ff;\">",
"          Unintentional injury&nbsp;",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #0000ff;\">",
"          7651",
"         </span>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Short gestation",
"        </p>",
"        <p>",
"         4538",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         464",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malignant neoplasms",
"        </p>",
"        <p>",
"         477",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malignant neoplasms",
"        </p>",
"        <p>",
"         419",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"red\">",
"          Homicide",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          1919",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          Homicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          2943",
"         </span>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        <p>",
"         SIDS",
"        </p>",
"        <p>",
"         2226",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          Homicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          376",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         195",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          Suicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          259",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          Suicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          1669",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          Suicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #008000;\">",
"          2702",
"         </span>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        <p>",
"         Maternal pregnancy comp.",
"        </p>",
"        <p>",
"         1608",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malignant neoplasms",
"        </p>",
"        <p>",
"         350",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"red\">",
"          Homicide",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          119",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          Homicide",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"color: #ff0000;\">",
"          186",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malignant neoplasms",
"        </p>",
"        <p>",
"         644",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malignant neoplasms",
"        </p>",
"        <p>",
"         992",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"blue\">",
"          Unintentional injury",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"blue\">",
"          1181",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease",
"        </p>",
"        <p>",
"         154",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Influenza &amp; pneumonia",
"        </p>",
"        <p>",
"         106",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         169",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease",
"        </p>",
"        <p>",
"         335",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease",
"        </p>",
"        <p>",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        <p>",
"         Placenta cord membranes",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         1064",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Influenza &amp; pneumonia",
"        </p>",
"        <p>",
"         146",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease",
"        </p>",
"        <p>",
"         97",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Influenza &amp; pneumonia",
"        </p>",
"        <p>",
"         122",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         230",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Influenza &amp; pneumonia",
"        </p>",
"        <p>",
"         255",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        <p>",
"         Bacterial sepsis",
"        </p>",
"        <p>",
"         652",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Septicemia",
"        </p>",
"        <p>",
"         71",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chronic low. respiratory disease",
"        </p>",
"        <p>",
"         64",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease",
"        </p>",
"        <p>",
"         120",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Influenza &amp; pneumonia",
"        </p>",
"        <p>",
"         163",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Congenital anomalies*",
"        </p>",
"        <p>",
"         227",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        <p>",
"         Respiratory distress",
"        </p>",
"        <p>",
"         595",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chronic low. respiratory disease",
"        </p>",
"        <p>",
"         66",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benign neoplasms",
"        </p>",
"        <p>",
"         40",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chronic low. respiratory disease",
"        </p>",
"        <p>",
"         59",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chronic low. respiratory disease",
"        </p>",
"        <p>",
"         86",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Complicated pregnancy",
"        </p>",
"        <p>",
"         169",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <p>",
"         Circulatory system disease",
"        </p>",
"        <p>",
"         581",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Perinatal period",
"        </p>",
"        <p>",
"         58",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Septicemia",
"        </p>",
"        <p>",
"         33",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benign neoplasms",
"        </p>",
"        <p>",
"         45",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Septicemia",
"        </p>",
"        <p>",
"         61",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cerebrovascular",
"        </p>",
"        <p>",
"         133",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <p>",
"         Neonatal hemorrhage",
"        </p>",
"        <p>",
"         517",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benign neoplasms",
"        </p>",
"        <p>",
"         53",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cerebrovascular",
"        </p>",
"        <p>",
"         32",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cerebrovascular",
"        </p>",
"        <p>",
"         42",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cerebrovascular",
"        </p>",
"        <p>",
"         60",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;HIV",
"        </p>",
"        <p>",
"         127",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Congenital malformation, deformations, and chromosomal abnormalities.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Newborn affected by complications of placenta, cord, and membranes.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Center for Health Statistics (NCHS), National Vital Statistics System. Available at:",
"     <a href=\"file://www.cdc.gov/injury/wisqars/leading_causes_death.html\" style=\"FONT-STYLE: italic\">",
"      www.cdc.gov/injury/wisqars/leading_causes_death.html",
"     </a>",
"     . Accessed on May 14, 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27102=[""].join("\n");
var outline_f26_29_27102=null;
var title_f26_29_27103="Jaw thrust maneuver";
var content_f26_29_27103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jaw thrust maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The jaw-thrust maneuver is used in the patient in whom cervical spine injury is a concern. This maneuver moves the tongue anteriorly with the mandible, minimizing the tongue's ability to obstruct the airway. With the patient supine and the clinician standing at the head of the bed, the technique is performed by placing the heels of both hands on the parieto-occipital areas on each side of the patient's head, then grasping the angles of the mandible with the index and long fingers, and displacing the jaw anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_29_27103=[""].join("\n");
var outline_f26_29_27103=null;
